

CURRICULUM VITAE

NAME Margaret Ann Tempero, M.D.

OFFICE ADDRESS  
University of California San Francisco
UCSF Comprehensive Cancer Center
1600 Divisadero Street, #B726
San Francisco, CA 94115

OFFICE PHONE 415.885.3846
415.353.9636 fax

EDUCATION

College

1965 -1967 University of San Francisco

1967 - 1969 Creighton University
B.S. Medical Technology

1972 - 1974 University of Nebraska Medical Center
M.S. Clinical Pathology

Graduate

1974 - 1977 University of Nebraska
M.D.

Postgraduate Training

1977 - 1980 University of Nebraska
Internal Medicine Residency

1980 - 1982 University of Nebraska
Fellow, Medical Oncology/Hematology

1981 - 1981 Memorial Sloan-Kettering
Visiting Research Fellow

ACADEMIC APPOINTMENTS

2000 - Present Deputy Director, Director of Clinical Science
UCSF Comprehensive Cancer Center

2000 - Present Professor, Division of Medical Oncology
Department of Medicine
University of California San Francisco

2000 - 2007 Chief, Division of Medical Oncology
Department of Medicine
University of California, San Francisco

1997 - 1999 Interim Director
UNMC/Eppley Cancer Center
(September 1996-February 1997, August 1997-July 1997,
January 1998-December 1999)

1995 - 1999 Deputy Director
UNMC/Eppley Cancer Center
University of Nebraska Medical Center

1994 - 1999 Professor of Medicine
Department of Internal Medicine
University of Nebraska Medical Center

1987 - 1994 Associate Professor of Medicine
Department of Internal Medicine
University of Nebraska Medical Center

1983 - 1987 Assistant Professor of Medicine
Department of Internal Medicine
University of Nebraska Medical Center

1983 - 1999 Chief of Oncology and Hematology
Omaha V.A. Medical Center

1994 - Present Professor (Courtesy)
Eppley Institute for Cancer Research

1987 - 1994 Associate Professor (Courtesy)
Eppley Institute for Cancer Research

1985 - 1987 Assistant Professor (Courtesy)
Eppley Institute for Cancer Research

CERTIFICATION

1985 - 1987 National Boards
1980 Diplomat, American Board of Internal Medicine
1983 Diplomat, Medical Oncology, ABIM
1984 Diplomat, Hematology ABIM

LICENSE

California [redacted]
Nebraska License [redacted]
Iowa License [redacted]
NPI [redacted]

GRANT/CONTRACT SUPPORT

ACTIVE GRANTS

P30 CA 82103-04 (McCormick) 08/01/02-05/31/07 40%
NCI \$4,732,522

Cancer Center Support Grant

This grant provides support for Cancer Center infrastructure and Program leadership.
Dr. Tempero is the Deputy Director for this grant.

U54 CA-00-001 04/01/01-12/31/07 15%
University of California San Francisco \$ [redacted] (direct)

Principal Investigator/Program Director "Interdisciplinary Research Teams for Molecular Target Assessment"

RECENT PAST

[redacted] 10/22/01-10/21/04 2%
In collaboration with [redacted] \$ [redacted] (total award)

Principal Investigator, "A Phase II Study of [redacted] Given in Combination with [redacted] for the Treatment of Metastatic Pancreatic Cancer"

3P50-CA72712-03S2 01/01/00-01/31/02 20%
University of Nebraska, HIH/NCI \$207,392

Principal Investigator of Project 1 – Part 1, Optimizing Radioimmunotherapy for Pancreatic Cancer; Major Goals: These trials will explore biodistribution and pharmacokinetics of this construct and the possibility of multi-dose treatment strategies. Overlap: None

Marc Lustgarten Foundation for Pancreatic Cancer 03/01/99-2/28/01
Principal Investigator - "Optimizing therapy for pancreatic cancer with TALL-104 cells" \$ [redacted]

1 P50 CA72712 9/01/97-8/31/00
NIH/NCI \$7,217,565 (total award)
Principal Investigator "Special Program of Research Excellence in Gastrointestinal Cancer"

[redacted] 11/16/98 – 11/30/99
Principal Investigator \$ [redacted]
"A phase II trial of [redacted] in patients with advanced pancreatic carcinoma"

[redacted] 11/19/98 – 11/30/99
Principal Investigator \$ [redacted]
"Phase III randomized study of [redacted] vs. [redacted] in pancreatic cancer patients that have

progressive disease following [REDACTED] treatment”

[REDACTED] 2/1/98 – 1/31/00
Principal Investigator \$ [REDACTED]
“A phase II multi-center study to determine the efficacy and safety of [REDACTED] with advanced colon cancer”

[REDACTED] 1/1/97 - 12/31/99
Principal Investigator \$ [REDACTED]
“A multi-center study evaluating the addition of [REDACTED] to [REDACTED] chemotherapy in subjects with refractory colorectal cancer.”

[REDACTED] 7/10/97 – 7/10/00
Principal Investigator \$ [REDACTED]
“A phase II, randomized multicenter comparison of the efficacy of [REDACTED] in four schedules of [REDACTED] in previously untreated advanced colorectal cancer”

[REDACTED] 7/1/96 – 6/30/99
Principal Investigator \$ [REDACTED]
“A randomized phase II comparison of two different infusion regimens of [REDACTED] therapy in patients with locally advanced or metastatic adenocarcinoma of the pancreas”

[REDACTED] 6/18/98 – 9/30/99
Principal Investigator \$ [REDACTED]
“A phase II dose range study of [REDACTED] for active specific immunotherapy of colorectal cancer”

1 U01CCA58272-01 9/30/93 - 9/29/00
NCI/NIH \$405,423
Principal Investigator -"Defining Toxicity and Benefit for Radioimmunotherapy"

**APPEARS THIS WAY
ON ORIGINAL**

HOSPITAL STAFF APPOINTMENTS

2000 - Present UCSF - Moffitt Long Hospital
1998 - 1999 Nebraska Health Systems
1983 - 1998 University of Nebraska Hospital
1983 - 1999 Omaha Veterans Hospital

HOSPITAL CONSULTING POSITIONS

Methodist Hospital – Omaha, Nebraska
St. Anthony's Regional Hospital – Carroll, Iowa
St. Francis Hospital – Grand Island, Nebraska
Grand Island Memorial Hospital – Grand Island, Nebraska
St. Joseph's Hospital – Omaha, Nebraska

HONORS AND AWARDS

1979 - 1980 Highest Achievement in Academic Obstetrics, (Medical school)
Chief Medicine Resident, Clarkson Hospital
Alpha Omega Alpha
Sigma Xi, Omaha Chapter
1984 - 1986 American Cancer Society Junior Clinical Faculty Fellowship
1987 American College of Physicians, Fellow
1987 Appointed Distinguished Cancer Research Professor, University of Nebraska
1982 Good Housekeeping's "400 Best Cancer Doctors in America" List
1997 - 1999 UNMC Distinguished Cancer Research Professor, Endowed Chair
1996, 1998 Best Doctors in America
2003 - 2004 Best Doctors in America
1999 Good Housekeeping's "318 Top Cancer Specialists for Women" List
2000 Thomas Schafer Annual Endowed Lectureship, Georgetown University
2000 – Present Doris and Don Fisher Distinguished Professor in Clinical Research
2002 – 2005 Castle Connolly Guides: America's Top Doctors
2003 Norbert and Suzanne Schnog Lecturer, Yale Cancer Center
2003 McPeak Lecturer, Memorial Sloan Kettering
2003 Medical Visionary Award, Pancreatic Cancer Action Network
Co-Chair, NIH, Progress Review Group in Pancreatic Cancer

PROFESSIONAL ORGANIZATIONS

American Association for Cancer Research, Member
American College of Physicians, Fellow
American Federation for Clinical Research, Member
American Gastroenterological Association, Member
American Society for Clinical Oncology, Member
International Association of Pancreatology, Member
Sigma Xi, Member

EDITORIAL BOARDS

1991 -1997	American Journal of Gastroenterology, Associate Editor
1993 - 2001	Digestive Diseases
1995 -1998	Annals of Internal Medicine
1998 -1999	Journal of Clinical Oncology
1998 - 2001	Oncology
1995 - 2000	Cancer Research, Associate Editor,
1998 - Present	Critical Reviews in Oncology/Hematology
1999 - 2002	Evidence Based Oncology, Associate Editor
2000 - 2003	American Journal of Medicine, Associate Editor
2001 - Present	Clinical Cancer Research, Associate Editor
2001 - Present	International Journal of Gastrointestinal Cancer
2002	NCCN Journal

SCIENTIFIC ADVISORY BOARDS

Not For Profit

1999 - Present	Pancreatic Cancer Action Network
1999 - Present	Lustgarten Foundation, 1999
2004 - Present	V Foundation
2007 - Present	Wayne D. Kuni and Joan E. Kuni Foundation

For Profit

2004 - Present	[REDACTED]
2003 - Present	[REDACTED]
1998 - Present	[REDACTED]
2002 - Present	[REDACTED]
2004 - Present	[REDACTED]
2004 - Present	[REDACTED]

EXTERNAL ADVISORY COMMITTEES

1997 - Present	Northwestern University, Robert H. Lurie Cancer Center, Member
1998 - Present	University of Colorado Cancer Center, Chair
1999 - Present	NCI, Board of Scientific Counselors, Member
2000 - Present	Bay Area Breast SPORE, Chair
2000 - 2002	Walther Cancer Institute Scientific Clinical Review, Member
2001 - Present	Arizona Cancer Center, Member, GI SPORE
2001 - Present	Oregon Health Science Hospital Cancer Institute, Member
2003 - Present	MD Anderson, Pancreas SPORE, Chair
2005 - 2006	NCI, Board of Scientific Counselors, Chair
2008 - Present	Food and Drug Administration - Oncologic Drugs Advisory Committee

NATIONAL PROFESSIONAL SERVICE

	American Association for Cancer Research (AACR)
1993 - Present	State Legislative Committee, Member
1994 - 1995	REDACTED
1994 - 1995	Rosenthal Award Subcommittee, Member
1994 - 1995	Welcome Oncology Clinical Research Scholar Awards Committee, Member
1995 - 1996	Special Memberships Committee, Member
1996 - 1997	Special Memberships Committee, Chairperson
1998 - 1999	Public Issues Committee, Member
1998	ASCO/AACR Program Committee Joint Workshop “Methods in Clinical Cancer Research”
1999 - 2000	Deputy Director
2000 - 2002	Co-Director
1999 - 2002	Special Conferences Committee, Member
1991 - 2001	Scientific Program Committee
2002 - 2003	Scientific Program Committee
2001 - 2002	Local Planning Committee - 2002 meeting
2004	AACR/Lustgarten Conference, Chairperson

AMERICAN COLLEGE OF PHYSICIANS

1996 - 1997	Publication Policy Committee, Member
1997 - 1998	Publications Committee, Member

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

1989 - 1991	Cancer Education/Training Committee, Member
1992 - 1994	Special Awards Committee, Member
1995 - 1996	Gastrointestinal Cancer Subcommittee ASCO Program Committee
2002	Chairperson
1996 - 1997	Annual Meeting Program Committee, Chairperson
1997 - 1999	American Joint Committee on Cancer, Sponsoring Member representing ASCO
1997 - 2000	American College of Surgeons, Commission on Cancer, Committee on Standards, ASCO Liaison, Member
1998	ASCO and Oncology Nursing Society Task Force, Chairperson
1998	ASCO/AACR Program Committee Joint Workshop “Methods in Clinical Cancer Research”,
1999	Deputy Director
2000 - 2002	Co-Director
1998 - 2001	Board of Directors, Member
1999	Speakers Bureau Program, Member
2001 - Present	Task Force on Associate/Junior Active ASCO Members, Leader,
1992 - 1996	Program Committee
2001 - 2003	Program Committee
2001 - 2004	Special Awards Selection Committee
2002 - 2003	Strategic Planning Committee of the Board, 2002-2003
2002 - 2003	President-elect
2003 - 2004	President
2004 - 2006	ASCO Foundation Board of Directors

CANCER AND LEUKEMIA GROUP B
 1996 - Present GI Core Committee, Member
 1996 Pancreatic Subcommittee, Chairperson
 1998 Conflict of Interest Committee, Member
 2001 - Present GI Intergroup Pancreas Cancer Tas

CELL KINETICS SOCIETY
 1988 - 1989 Nominating Committee, Member

INTERNATIONAL ASSOCIATION OF PANCREATOLOGY
 1998 - 2000 Council Member
 2003 - 2006

NATIONAL CANCER INSTITUTE/NATIONAL INSTITUTES OF HEALTH
 1992 Consensus Development Conference on Diagnosis and Treatment of Early Melanoma, Panel Member
 1995 - 1999 NCI/NIH Cancer Centers & Research Programs Review Committee – Subcommittee A, Member
 1998 - 1999 NIH Committee, Clinical Oncology Special Emphasis Panel, Chair
 1999 - 2004 NCI Board of Scientific Counselors, Subcommittee A, Group One
 2004 - 2006 Member; Chair
 2001 Progress Review Group for Pancreatic Cancer, Co-Chair

NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN)
 1995 - 1997 Executive Board, Member
 1997 - 2001 Vice-Chair
 1995 - 2001 Colorectal Cancer Guidelines Committee, Member
 1996 - Present Pancreatic Cancer Guidelines Committee, Chair
 1997 - Present CME Advisory Committee, Member

REGIONAL SERVICE

1992 Veteran's Administration Regional Oncology Advisory Committee
 1986 American Cancer Society, Professional Education Committee, Vice Chairperson
 2001 - Present Association of Northern California Oncologists, UCSF Representative to the Board of Directors
 2005 UCSF Osher Lifelong Learning Institute, Course Organizer

INSTITUTIONAL PROFESSIONAL SERVICE

UNIVERSITY OF CALIFORNIA SAN FRANCISCO
UCSF – Wide
 2000 - 2002 Hellman Award Committee
 2001 - 2003 Ambulatory Services Committee
 2001 – 2002 Mount Zion Subcommittee of the Chancellor's Advisory Committee on the 2002 LRDP Amendment
 2000 - Present Clinical Research Executive Committee
 2002 - 2006 Medical Staff Committee

- UCSF – School of Medicine
- 2000 - Present Clinical Practice Organization
 - 2000 - 2004 Clinical Practice Organization, Finance Subcommittee
 - 2000 - Present Fundraising Advisory Council
 - 2000 - Present School of Medicine Clinical Research Executive Committee
 - 2001 - Present Department of OB-Gyn Oncology Chief, Search Committee
 - 2001 Department of Otolaryngology Chief, Search Committee
 - 2000 - Present Department of Orthopedics Chairperson, Search Committee
 - 2000 - Present Dean's Strategic Planning Committee
 - 2002 Physician Scientist Program Clinic-based Task Force (PSPC)
 - 2003 School of Medicine Associate Chair for Clinical Research, Search Committee
 - 2003 - Present Steering Committee for Physician Scientist Program – Clinic Based
 - 2005 Department of Radiation Oncology Chairperson
 - 2005 Chair of Search Committee
- UCSF – Department of Medicine
- 2001 - Present Chief, Hematology and Oncology – San Francisco Veteran Medical Center, Search Committee
- UCSF Comprehensive Cancer Center
- 2000 – Present Executive Committee
 - 2000 – Present Strategic Planning Committee
 - 2000 – 2003 Clinical Activities Executive Committee, Chair
 - 2000 - Present Program Planning Committee
 - 2001 - Present ACS Institutional Research Grant Review Committee
 - 2001 Assistant Director of Education and Outreach, Search Committee
 - 2001 - 2002 Cancer Center Funds Flow Committee, Co-chair
 - 2000 - Present Cancer Center CIRP Award Committee, Chair
 - 2001 - Present Ethel and Jane Sokolow Memorial Cancer Endowment Lectureship Committee
 - 2002 - Present Cancer Center Operations Group, Chair
 - 2003 - Present Cancer Center Directors Group
 - 2003 Associate Director-Administration Search Committee,
 - 2003 - Present Cancer Center Minority Task Force
- Other
- 2000 - Present Mount Zion Health Fund, Board of Directors

UNIVERSITY OF NEBRASKA COMMITTEES:

- College of Medicine Committees
- 1987 – 1988 Alpha Omega Alpha, Alumni and Faculty Committee - Member
 - 1989 – 1992 Alpha Omega Alpha Committee for Visiting Professorship and Scholarly Pursuits, Member
 - 1992 – 1999 Chairperson
 - 1997 Chancellor's Leadership Council, Member
 - 19959 – 1999 College of Medicine Strategic Plan - Cancer Committee, Chairperson
 - 1996 Faculty Council, Ad-Hoc Member
 - 1988 – 1994 Faculty Senate, Member
 - 1997 – 1999 Leadership Council, Member
 - 1994 Mission Statement Committee, Member

- 1986 - 1992 Scholastic Evaluation Committee, Member
- 1989 - 1991 University of Nebraska Honors and Awards Committee, Chairperson
- 1992 - 1995 UNMC Campus Commission on Gender Related Issues, Member
- 1992 UNMC College of Medicine Dean's Search Committee, Member
- 1994 - 1996 UNMC Curriculum Oversight Committee, Chairperson
- 1996 [REDACTED]
- 1992 - 1998 [REDACTED]
- 1994 - 1995 [REDACTED]
- 1995 - 1998 [REDACTED]
- 1994 - 1995 UNMC Faculty Recruitment, Development & Rewards Sub-Committee, Member
- 1996 - 2000 UNMC Clinical Advisory Committee of the Clinical Research Center, Member
- 1997 - 1998 Radiation Oncology Chair Search Committee, Chairperson
- 1997 - 1999 Liaison Committee on Medical Education Self Study Task Force, Member

Hospital Committees

- 1995 - 1999 Oncology Service Line Committee, Member
- 1994 - 1999 National Comprehensive Cancer Network, UNMC Steering Committee, Chairperson
- 1984 - 1985 Pharmacy & Therapeutics Committee, Member;
- 1985 - 1988 Chairperson
- 1985 - 1988 Quality Assurance Committee, Member
- 1991 - 1999 Clinical Cancer Center Administrative Committee, Member
- 1992 - 1995 Distinction Through Quality, University East Committee, Member
- 1993 UNMC Home Health Care Selection Committee, Member
- 1994 - 1999 Research Committee for UNMC Lied Transplant Center, Member

Departmental Committees:

- 1984 - 1995 Graduate Education Committee, Member
- 1994 - 1997 Internal Medicine Clinical Section Team, Member
- 1994 - 1996 Internal Medicine Gender Equity Committee, Chairperson

OMAHA VETERAN'S ADMINISTRATION COMMITTEES

- 1984 - 1985 Veteran's Administration Subcommittee on Animal Use, Member
- 1986 - 1989 Veteran's Administration Committee on Research & Development, Member
- 1987 - 1999 Veteran's Administration Blood Transfusion Committee, Chairperson

GRADUATE STUDENT ADVISOR

- 1984 - 1988 [REDACTED] Ph.D. advisor
- 1989 - 1991 [REDACTED] M.D., Post doctoral advisor
- 1991 - 1994 [REDACTED] Ph.D. advisor
- 1997 - 2001 [REDACTED] Ph.D. Supervisory Committee
- 1997 - 2002 [REDACTED] Ph.D., Supervisory Committee
- 2002 - 2004 [REDACTED] Ph.D., Supervisory Committee

PUBLISHED PAPERS IN PROFESSIONAL JOURNALS

1. Tempero MA and Smith PW: Disseminated mycobacterial kansasii presenting with skin lesions in a patient with chronic lymphocytic leukemia. *Medical & Pediatric Oncology* 9:283-288, 1981.
2. Tempero MA, Foley JF and Kessinger A: VP-16-213 therapy after failure with combination chemotherapy for small cell carcinoma of the lung. *Clinical Cancer Trials* 4:155-157, 1981.
3. Tempero MA, Petersen R, Zetterman RK and Lemon HM: The liver scan and biochemical liver tests in the detection of metastatic disease. *JAMA* 248:1329-1332, 1982.
4. Tempero MA and Kessinger A: Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma. *J Surg Oncology* 21:159-161, 1982.
5. Tempero MA, Lynch HT, Jacobs M, Graham C and Blotcky A: Selenium levels in hereditary non-polyposis colorectal cancer. *Biol Trace Elements Res* 6:51-55, 1984.
6. Tempero MA, West W, Zetterman RK: The effect of increasing amounts of dietary cellulose fiber in the presence of dietary cholesterol in experimental colon cancer. *J of Nutrition, Growth & Cancer* 1: 197-206, 1984.
7. Tempero MA, Davis RB, Reed E, and Edney J.: Thrombocytopenia and Laboratory Evidence of Disseminated Intravascular Coagulation after Shunts for Ascites in Malignant Disease. *Cancer* 55:2718-2721, 1985.
8. Berg AR, Linder J, Anderson RA, Tempero MA, Edney JA, Armitage JO: The Undifferentiated Malignant Neoplasm: Identification of Lymphoma Arising in Skeletal Muscle by Immunohistochemistry. *JAMA* 254:2625-2626, 1985.
9. Thompson JS, Tempero MA, Haun JL and Vanderhoof JA: The importance of luminal factors in neomucosal growth. *J Surg Res* 40:126-132, 1986.
10. Tempero MA: Bile Acids, Ornithine Decarboxylase and Cell Proliferation in Colon Cancer: A Review. *Survey Dig Dis* 4:49-56, 1986.
11. Tempero MA, Van de Walle C and Anderson J: The Value of Hepatic Ultrasound and Biochemical Liver Tests in Screening for Liver Metastases. *J Clin Oncol* 4:1074-1078, 1986.
12. Tempero MA, Deschner EE and Zedeck MS. The Effect of Selenium on Cell Proliferation in Liver and Colon. *Biol Trace Elements Res* 10:145-152, 1986.
13. Herlyn D, Sears H, Dimitris I, Lubeck M, Douillard J, Sindelar W, Tempero MA, Meelsted H, Maher M, and Koprowski H. Anti-idiotypic Antibodies to Monoclonal Antibody CO17-1A. *Hybridoma* 5:Supl 1:S51-S58, 1986.
14. Tempero MA, Pour PM, Uchida E, Herlyn D, and Steplewski Z: Monoclonal Antibody CO17-1A and Leukopheresis in Immunotherapy of Pancreatic Cancer. *Hybridoma*, 5:Supl 1: S133-S138. 1986.
15. Petrie H, Tempero MA, Klassen L and Kay D: In Vitro Regulation of Human Lymphocytic Proliferation by Selenium. *Biol Trace Element Res*, 11:129-146, 1986.

16. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, and Pour PM. Comparative studies on expression of CA 19-9 and Du-Pan-2 in Pancreatic Cancer Tissue. *International J Pancreat* 2:349-360, 1987.
17. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, and Pour PM: The Relationship of CA 19-9 and Lewis Antigens in Pancreatic Cancer. *Cancer Res* 47:5501-5503, 1987.
18. Uchida E, Tempero MA, Burnett DA, Steplewski Z, and Pour PM. Correlative studies on antigenicity of pancreatic cancer and blood group types. *Cancer Detection and Prevention Suppl* 1:145-148, 1987.
19. Tempero MA, Zetterman RK: The Effects of Sodium Cholate on Experimental Carcinogenesis and Cell Proliferation in an Isolated Colonic Segment. *J. Surg. Onc.* 36:253-258, 1987.
20. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RG and Pour PM. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of patients with pancreatic cancer. *Cancer Research* 2:349-360, 1987.
21. Ness MJ, Pour PM, Tempero MA, and Linder J. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. *Modern Pathology* 1:279-283, 1988.
22. Pour PM, Tempero MA, Takasaki H, Uchida E, Takiyama Y, Burnett DA and Steplewski Z. Expression of blood group-related antigens, ABH, Lewis a, Lewis b, Lewis x and Lewis y and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. *Cancer Research* 48:5422-5426, 1988.
23. Takasaki H, Tempero MA, Uchida E, Buchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J and Pour PM. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. *Int J Cancer* 42:681-686, 1988.
24. Tempero MA, Knott K, and Zetterman RA. The Relationship of Dietary Cholesterol and Cellulose in the Prevention of Colon Cancer. *Journal of Cancer Detection and Prevention* 13:41-54, 1988.
25. Tempero MA, Takasaki H, Uchida E, Takiyama Y, Colcher D, Metzgar RS and Pour PM. Co-expression of CA 19-9, CA 125 and TAG-72 in pancreatic carcinoma. *Amer J Surg Path* 13(Suppl 1):89-95, 1989.
26. Tempero MA, Nishioka K, Knott K and Zetterman RK. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. *Cancer Research* 49:5793-97, 1989.
27. Wettendorf M, Iliopoulos D, Tempero MA, Kay HD, DeFreitas E, Koprowski H, Herlyn D. Idiotypic networks in cancer patients treated with monoclonal antibody CO17-1A. *Proc Natl Acad Sci* 86:3787-91, 1989.
28. Tempero MA: Advances in the medical management of advanced gastrointestinal cancers. *Current Opinions in Oncology* 2:747-753, 1990.

29. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, and Kay HD: Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: Biologic and clinical effects. *J Clin Oncol* 12:2019-2026, 1990.
30. Egami H, Tsutomu T, Tempero MA, Kay D, Pour PM. Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters. *Amer J Pathology* 138:557-561, 1991.
31. Tempero MA. Progress in chemoprevention of gastrointestinal cancers. *Curr Opinion in Oncology* 3:719-726, 1991.
32. Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, and Pour P. Immunotherapy with monoclonal antibody (MAB) in pancreatic adenocarcinoma. *Int J Pancreatol* 9:125-134, 1991.
33. Haga Y, Kay HD, Tempero MA, Zetterman R. Characterization of bilirubin transport system by human peripheral blood mononuclear cells. Evidence of preferential uptake of bilirubin by monocytes. *J Leukocyte Biology* 51:2-6, 1992.
34. Haga Y, Sivinski CL, Kay HD, McDonald TL, Khazaeli MB, Blottier HM, Steplewski Z, Harvey E, and Tempero MA. Biologic responses to multiple high doses of murine monoclonal antibody (17-1A) in pancreatic cancer patients. *Antibody Immunonconj Pharm* 5:179-190, 1992.
35. Hirota M, Pour PM, Tempero MA and Chaney WG: Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas. *Carcinogenesis* 13:1829-1833, 1992.
36. Haga Y, Kay HD, Tempero MA, and Zetterman R. Flow cytometric measurement of intracellular bilirubin in human peripheral blood mononuclear cells exposed to unconjugated bilirubin. *Clin Biochem* 25:277-283, 1992.
37. Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG. Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-1A fragments. *Tumor Biol* 13:195-206, 1992.
38. Tempero, MA. Pitfalls in antibody imaging in colorectal cancer. *Cancer* 71, 4248, 1993.
39. Tempero MA, Colcher D, Dalrymple G, Harrison K, Holdeman K, Joshi S, Quadri S, Linder J, Augustine S, Reed E, and Leichner P. Cancer therapy using radioimmunoconjugates: Implications for breast cancer. *Ann NY Acad Sci*, 698:406-417, 1993.
40. Haga Y, Sivinski CL, Woo D, and Tempero MA. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A: Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. *Int J Pancreatol*, 15:43-50, 1994.
41. Tempero M. The emerging uses of radioimmunoconjugates in the management of gastrointestinal cancers. *Hem/Onc Ann*, 2:213-224, 1994.
42. Tempero M and Anderson J. Editorial: Progress in colon cancer - Do molecular markers matter? *N Engl J Med* 311:267-268, 1994.

43. Tempero M, Berg A, Block M, Hutchins M, Langdon R, Moravec D, Tweedy C, and Anderson J. A phase II trial of protracted therapy with 5-Fluorouracil and daily oral leucovorin in metastatic colorectal cancer. *J Infusional Chemotherapy* 4:112-115, 1994.
44. Kornbot B, Kobayashi RH, Singer A, Tempero M, and Heiner D. Hypersensitivity to therapeutic murine monoclonal antibodies. *Nebr Med Journal* 79:393-398, 1994.
45. Tempero MA, Haga Y, Sivinski C, Birt D, Klassen L, and Thiele G. Immunologic effects of levamisole in mice and men: Evidence for augmented antibody response without modulation of cellular cytotoxicity. *Journal of Immunotherapy* 17:47-57, 1995.
46. Kessinger A, Bishop M, Anderson J, Armitage J, Bierman P, Reed E, Tarantolo S, Tempero M, Vose J: A comparison of subcutaneous and intravenous administration of rhGM-CSF for peripheral blood stem cell mobilization. *J Hematotherapy* 4:81-84, 1995.
47. McCashland RM, Bashir R, Tempero MA and Quigley EMM. Dysphagia and diffuse esophageal spasm as the presenting manifestation of a glucagonoma-neuropathy syndrome. *Diseases of the Esophagus*, 8:74-77, 1995.
48. Tan-Shalaby J and Tempero M: Malignancies after liver transplantation: A comparative review. *Semin Liver Dis* 15:156-164, 1995.
49. Sivinski CL, Lindner DJ, Borden EC, and Tempero MA: Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells *in vitro* by alpha and gamma interferons. *J Immunotherapy* 18:156-165, 1995.
50. Tempero MA, Brand R, Holdeman K, and Matamoros: A New imaging techniques in colorectal cancer. *Semin Oncol* 22:448-471,1995.
51. Harrison KA and Tempero MA: Diagnostic use of radiolabeled antibodies for cancer. *Oncology* 9:625-63,1995.
52. Haga Y, Tempero MA, Rowen K and Zetterman R: Unconjugated bilirubin inhibits *in vitro* cytotoxic T lymphocyte activity of human lymphocytes. *Biochimica et Biophysica Acta* 1317:65-70, 1996.
53. Haga, Y, Tempero, MA, Rowen, K, Zetterman, R: Unconjugated bilirubin inhibits *in vitro* major histocompatibility complex-unrestricted cytotoxicity of human lymphocytes. *Biochimica et Biophysica Acta* 1316:29-34, 1996.
54. Haga Y, Tempero MA, Kay D, and Zetterman R: Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutinin-induced proliferation and interleukin-2 production of human lymphocytes. *Digestive Diseases and Science* 41:1468-1474, 1996.
55. Engstrom P, Benson AB, Cohen A, Doroshov J, Kiel K, Niederhuber J, Roh M, and Tempero M: NCCN colorectal cancer practice guidelines. *Oncology* 10:140-175, 1996.
56. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, and Chiou RK: Radiolabeled iododeoxyuridine: Safety evaluation. *J Nucl Med* 37:13-16, 1996.

57. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, and Colcher D: Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. *J Clin Immunol* 17:96-106, 1997.
58. Tempero, MA: Walking a difficult path is easier with a friend: Thoughts from a practicing oncologist. *Ann New York Academy of Sciences* 809:237-242, 1997.
59. Tempero MA, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Wisecarver J, and Colcher D: High dose therapy with ¹³¹I labeled monoclonal antibody CC49: A phase I trial. *J Clin Oncol*, 15:1518-1528, 1997.
60. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver JA, and Tempero MA: Patient-specific dosimetry of Indium-111/Yttrium-90-labeled monoclonal antibody CC49. *J Nucl Med* 38:512-516, 1997.
61. Tempero MA: Review: Recent progress in radioimmunotherapy cancer. Meridith RF and LoBuglio AF (authors). *Oncology* 11:987, 1997.
62. Habbe TG, McCowan TC, Goertzen TC, LeVeen RF, and Tempero MA: Arterial infusion chemotherapy in the treatment of isolated hepatic colorectal metastases. *Semin Interventional Radiology* 14:241-53, 1997.
63. Tempero MA, Abbruzzese J, Benson AB, Cameron JL, Casper ES, Hoffman J, Lawrence T, Martin T, McGinn C, and Willett C: NCCN practice guidelines for pancreatic cancer. *NCCN Proceedings, Oncology* 11:41-56, 1997.
64. Habbe TG, McCowan TC, Goertzen TC, LeVeen RF, and Tempero MA: Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. *Journal of Vascular and Interventional Radiology* 8(1):221, 1997.
65. Brand R, Capadano M, and Tempero M: A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with non-hematologic malignancies. *Invest New Drugs* 15:331-341, 1997.
66. Habbe TG, McCowan TC, Goertzen TC, LeVeen RF, Culp WC, and Tempero MA: Complications and technical limitation of hepatic arterial infusion catheter placement for chemotherapy. *Journal of Vascular and Interventional Radiology* 9:233-239, 1998.
67. Brand RE and Tempero MA: Pancreatic cancer. *Curr Opin Oncol* 10:362-366, 1998.
68. Tempero M: Pancreatic Cancer. *Clin Perspectives in Gastroenterology* 1:96-100, 1998.
69. Tempero M and Brand R: Letter to the Editor, Fatal pulmonary toxicity resulting from treatment with gemcitabine. *Cancer* 82:1800-01, 1998.
70. Tempero M: Chemotherapy for Pancreatic Adenocarcinoma. *Journal of Gastrointestinal Surgery*, July/August 1999.
71. DiMagno EP, Reber HA, and Tempero MA: AGA Technical Review and Medical Position Statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. *Gastroenterology*, 117:1463-1484, 1999.

72. Tempero M: Commentary: Irinotecan increased survival in patients with advanced colorectal cancer. Evidence-based Oncology, Preview Issue, 2000.
73. Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, Leichner P, Lynch JC, Goldenber D, and Armitage JO: Phase I/II trial of multiple dose ¹³¹Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leukemia and Lymphoma, 38: 91-101, 2000.
74. Gwilt PR, Tempero MA, Kremer A, Connolly M, and Ding C: Pharmacokinetics of levamisole in patients treated with 5-Fluorouracil. Cancer Chemother Pharmacol., 45(3):247-51, 2000.
75. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryant K, Fisher DR, Colcher D, Horak ID, and Weiner LM: Phase II trial of yttrium-90-DOTA-BIOTIN targeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clinical Cancer Research 6:406-412, 2000.
76. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, and Colcher D: High dose therapy with ⁹⁰Yttrium labeled monoclonal antibody CC49: A phase I trial. Clin Cancer Res. 6:3095-3102, 2000.
77. Vose, J, Colcher, D, Gobar, L, Bierman, PJ, Augustine, S, Tempero, MA, Leichner, P, Lynch, JC, Goldenberg, D, Armitae, JO: Phase I/II trial of multiple dose ¹³¹iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma, Leukemia and Lymphoma. 38: 91-101, 2000.
78. Goel, A, Augustine, S, Baranowska-Kortylewicz, J, Colcher,D, Booth, B, Pavlinkova, G, Tempero, M, and Batra, S. Single -dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using ¹³¹I-labeled multivalent CC49 single chain Fvs. Clin Cancer Res. 7:175-84, 2001
79. Rutar, FJ, Augustine, SC, Colcher, D, Siegel, JA, Jacobson, DA, Tempero, MA, Dukat, VJ, Hohenstein, MA, Gobar, LS, Vose, JM. Outpatient Treatment with ¹³¹I-anti-B1 antibody: radiation exposure to family members. J. Nucl Med. 42:907-915, 2001.
80. Copur MS, Capadano M, Lynch J, Goertzen T, McCowan T, Brand R, Tempero M. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. J Clin Oncol, May 1;19(9):2404-12. 2001.
81. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. A white paper: the product of a pancreas cancer think tank. Cancer Res, Jun 15;61(12):4923-32, 2001.
82. Augustine, S, Norenberg, J, Colcher, D, Vose, J, Gobar, L, Dukat, V, Hohenstein, M, Rutar, F, Jacobson, D, Tempero, M. Combination therapy for non-hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J of Amer Pharma Association 42:93-100, 2002.
83. Ko, A, Tempero, MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep, 12: 39-45, 2002.

84. Kurizaki, T, Okazaki, S, Sanderson, S, Colcher, D, Enke, C, Tempero, M, Baranowska-Kortylewicz, J. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. *J of Nuc Med*, 43 (7): 957-67, 2002.
85. Sudan, D, DeRoover, A, Chinnakotla, S, Fox, I, Shaw, B Jr., McCashland, T, Sorrell, M, Tempero, M, Langnas, A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. *Am J Transplant*. 2(8): 774-9, September 2002.
86. Tempero, M, Plunkett, W, Ruiz van Haperen, V, Hainsworth, J, Hochster, H, Lenzi, R, Abbruzzese, J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. *J Clin Oncol*. September 15; 21 (18); 3402-8, 2003.
87. Blackstock, A., Tepper, J, Niedwiecki, D, Hollis, D, Mayer, R, Tempero, MA. Cancer and Leukemia Group B (CALGB) 89805: Phase II Chemoradiation Trial Using Gemcitabine in Patients with Locoregional Adenocarcinoma of the Pancreas. *IJGC*, vol 34/2, pp 109-118, 2004.
88. Ko, A.H., Hwang, J., Venook, A.P., Abbruzzese, J., Bergsland, E.K, Tempero, M.A. Serum CA 19-9 response as a surrogate for clinical outcome in patients with advanced pancreatic cancer treated with fixed-dose rate gemcitabine. *Brit J Cancer*, 93(2):195-9, July 2005.
89. Ko, A.H., Tempero, M.A. Treatment of metastatic pancreatic cancer. *J NCCN*, 3(5):627-36, September 2005.
90. Ko, A.H., Tempero, M.A. Systemic therapy for pancreatic cancer. *Semin Radiat Oncol* 15(4):245-53, October 2005.
91. Hruban, R.H., Rustgi, A.K., Brentnall, T.A., Tempero, M.A., Wright, C.V., and Tuveson, D.A. Pancreatic Cancer in Mice and Man: The Penn Workshop 2004. *Cancer Res* 66(1): 14-7, January, 2006.
92. Ko, A.H., Dito, E., Schillinger, B., Venook, A.P., Bergsland, E.K., Tempero, M.A. Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas. *J Clin Oncol*. 24(3): 379-85, January 2006.
93. Jhaver, M, Rosen, L, Dancy, J, Hochster, H, Hamburg, S, Tempero, M.A., Clendeninn, N, Mani, S. Phase II Trial of Nolatrexed Dihydrochloride [Thymitaq, AG 337] in Patients with Advanced Hepatocellular Carcinoma. *Invest New Drugs*. 25(1):85-94, February, 2007.
94. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate Gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. (In Press).

PUBLICATIONS

1. Ratain, M, Tempero, M, Skosey, C. **Outline of Oncology Therapeutics**. W.B. Saunders Company, 2001.
2. Dollinger, M, Rosenbaum, E, Tempero, M. **Everyone's Guide to Cancer Therapy**, Somerville House Books Limited, 2001.

BOOK CHAPTERS / MONOGRAPHS

1. Tempero MA, Uchida E, Takasaki H, Kay HD, and Pour PM. Biologic studies in pancreatic cancer. **In: New Trends in Gastroenterology** Sugahara K, Ed; pp 135-151, 1987.
2. Armitage JO, Gingrich RD, Foley JF, Kessinger MA, Klassen LW, Kumar PP, Tempero MA, and Vaughan WP. Which Patient with Lymphoma Can Be Salvaged with High-Dose Cytoreduction and Autologous Marrow Rescue? **In: Autologous Bone Marrow Transplantation: Proc 1st International Symposium** Dicke KA, Spitzer G and Zander AK, Eds; pp 57-62, 1985.
3. Pour PM and Tempero MA. Blood Group Antigenicity of Gastrointestinal Cancers. **In: New Tumor Markers and their Monoclonal Antibodies** (Klapdor R, Ed); pp 315-318, 1987.
4. Tempero MA: Genetics of Colon Cancer at the Infrahuman Level. **In: Genetic Epidemiology of Cancer** (Lynch H and Hirayama T, Eds.), CRC Press, Inc.; 1989.
5. Pour PM, Egami H, Chaney WG, Takiyama Y, Tempero MA, Schlom J, and Colcher D. Comparative studies on antigen expression in human and experimental pancreatic cancer. **In: Recent Results in Tumor Diagnosis and Therapy** (R Klapdor, Ed) Zuckschwerdt Verlag Munchen · Bern · San Francisco; pp 293-296, 1990.
6. Tempero MA. Carcinoma of the Pancreas. **In: Current Therapy in Oncology**, JF Foley and JM Vose (Eds), WB Saunders; pp 57-62, 1994.
7. Tempero MA. General Application of Monoclonal Antibodies. **In: Current Therapy in Oncology**, JF Foley and JM Vose (Eds), WB Saunders; pp 399-402, 1994.
8. Tempero MA and Rasmussen B. Upper Gastrointestinal Cancer. **In: Current Cancer Therapeutics**, J. M. Kirkwood, M. T. Lotze and J. M. Yasko (eds), Current Medicine publisher; pp 91-104, 1994.
9. Tempero MA. Tumor of the Pancreas. **In: American College of Gastroenterology 1995 Annual Postgraduate Course Syllabus**, EMM Quigley, Course Director and BA Lashner and ML Schiffman, Course Co-Directors; pp 365-378, 1995.
10. Tempero MA and Rasmussen B. Upper Gastrointestinal Cancer. **In: Current Cancer Therapeutics - Second Edition**, J.M Kirkwood, M. T. Lotze, and J.M Yasko (eds), Churchill Livingstone publisher developed by Current Medicine; pp 128-143, 1996.
11. Tempero MA and Colcher DC. Radiolabeled Monoclonal Antibodies: Therapy of Solid Tumors. **In: Encyclopedia of Cancer**, JR Bertino (ed), Academic Press, Inc.; vol III pp. 1448-1458, 1997.
12. Tempero MA. Update on the Medical Management of Advanced Colon Cancer. **In: Progress in Anti-Cancer Chemotherapy**, D Khayat and G Hortobagyi (eds), Blackwell Science, Inc; pp. 149-160, 1997.
13. Tempero MA. Chemotherapy of Pancreatic Cancer. **In: Advances in Pancreatic Cancer**, H Reber (ed), Humana Press, Totowa, NJ, pp 265-280, 1998.

14. Tempero MA, Vaziri IA, and Rasmussen B. Upper Gastrointestinal Cancer. **In: Current Cancer Therapeutics - Third Edition**, J.M Kirkwood, M. T. Lotze, and J.M Yasko (eds), Churchill Livingstone publisher developed by Current Medicine, pp 137-155, 1998.
15. Tempero MA. Biological Approaches to the Therapy of Pancreatic Cancer. **In: Pancreatic Disease: State of the Art and Future Aspects of Research**, PG Lankisch and EP DiMagno (eds), Springer-Verlig Berlin Heidelberg New York, pp 221-229, 1998.
16. Brand RE and Tempero MA. Carcinoma of the Pancreas.. **In: Current Therapy in Oncology - 2nd Edition**, JF Foley, JM Vose, and JO Armitage (Eds), WB Saunders, pp 74-80, 1999.
17. Tempero MA. Biologic Therapy of Gastrointestinal Cancer. **In: Gastrointestinal Oncology**, AB Benson III (ed), Kluwer Academic Publishers, Norwell, MA, pp 227-237, 1999.
18. Tempero M. Advances in the Management of Pancreatic Cancer. **In: Progress in Anti-Cancer Chemotherapy**, GN Hortobagyi and D Khayat (Eds), Springer-Verlag France, Berlin, Heidelberg, pp 295-304, 1999.
19. Yeo, C, Abrams, R, Tempero, M. Pancreas Cancer: Clinical Management. **In: Principles and Practice of Gastrointestinal Oncology**, Lippincott, Williams, & Wilkins, Baltimore, MD. 2001.
20. Tempero, M, Kern, S., Conley, B., **Pancreatic Cancer: An Agenda for Action: Report of the Pancreatic Cancer Progress Review Group (PRG)**. NCI/NIH Publication 01-4940, February 2001.
21. Staveley-O'Carroll, K, Zeh, H, Tempero, M. Upper Gastrointestinal Cancer. **In: Current Cancer Therapeutics- 4th Edition**, Current Medicine, Inc. Philadelphia, 2001.
22. Tempero, M, Brand, R. Carcinoma of the Pancreas. **In: Cecil Textbook of Medicine**, Harcourt Health Sciences Companies. Philadelphia, pp 1220-1222, 2004; revised 2006.
23. Tempero, M, Termuhlen, P, Brand, R, McGinn, C. **In: Gastrointestinal Oncology**, Oxford University Press, New York, pp 377-385, 2004.
24. Ko, A., Tempero, M. Monoclonal Antibodies and Other Targeted Therapies. **In: Von Hoff DD, Evans DB, and Hruban RH (eds). Pancreatic Cancer**. Boston: Jones and Bartlett, 2005.
25. Ko, A., Tempero, M. Pancreatic Cancer: Adjuvant Therapy. **In: Mcculloch, P., Kerr, D., and Ajani, J. (eds). Gastrointestinal Oncology: Evidence and Analysis**. For publication in 2006.

ABSTRACTS

1. Tempero MA, Foley JF and Kessinger A: VP-16-213 after failure with combination chemotherapy for small cell carcinoma of the lung. Proc ASCO 21:460, 1980.
2. Tempero MA, West W, Zetterman RK: Failure of dietary cellulose fiber to prevent colon tumors in dimethylhydrazine (DMH)-treated rats on high cholesterol diets. Gastroenterology 80:1301, 1981.
3. Tempero MA, Petersen R and Lemon HM: The clinical usefulness of liver scans and liver chemistries in detecting metastatic malignant disease. Proc ASCO 22:C-208, 1981.
4. Tempero MA, West W, and Zetterman RK: The effect of dietary fiber and high cholesterol on colon tumor incidence and size in DMH-treated rats. Proc AACR 22:442, 1981.
5. Tempero MA, West W and Zetterman RK: The protective effect of dietary in the presence of dietary cholesterol in dimethylhydrazine (DMH)-induced colon cancer. Proc AACR 23:276, 1982.
6. Tempero MA, Kessinger A and Lemon HM: Hexamethylmelamine and L-PAM as second-line therapy in ovarian carcinoma. Proc ASCO 1:16, C-450, 1983.
7. Tempero MA and Zetterman RK: The effect of diet on thymidine (3H-TdR)- labeling of colon mucosa in diemthylhydrazine (DMH)-treated rats. Proc AACR 24:97, 1983.
8. Reed E, Tempero MA, Edney J and Foley JF: Disseminated intravascular coagulation (DIC), a complication of peritoneovenous shunts for malignant ascites. Proc ASCO 2:86, C-334, 1983.
9. Tempero MA, Vandewalle C and Anderson J: Sensitivity and specificity of hepatic ultrasound in the diagnosis of liver metastases. Proc ASCO 3:9, C-33, March 1984.
10. Rosenberg M, Tempero MA and Zetterman RK: Local effect of bile on colon crypt cell proliferation. Proc AACR 25:79, 311, March 1984.
11. Zetterman RK, Tempero MA, Baker H, Chen T and Frank O: Anti-Vitamin Therapy May Suppress DMH-Induced Colon Adenocarcinoma Expression. Gastroenterology 86:1307, 1984.
12. Thompson JS, Tempero MA, Haun JL, Vanderhoof JA: The Importance of Luminal Factors in Neomucosal Growth. Gastroenterology 86:1281, 1984.
13. Tempero MA and Graham CL: Effect of Selenium on 3H-TdR Uptake in Colon Tissue. Cell Kinetics Society, 1985.
14. Reed E, Tempero MA, Foley J, Mailliard J and Johnson S: Cisplatinum and Vinblastine Therapy in Non-Small Cell Lung Cancer. Proc ASCO 4:187, C-731, 1985.
15. Reed E and Tempero MA: The Effect of Diet on Radiation-Induced Changes in Gastrointestinal Cell Proliferation. Proc AACR 26:68, 269, 1985.
16. Petrie HT, Tempero MA, Klassen LW and Kay HD: Reversible inhibition of human lymphoproliferative response by selenium. FASEB 1985.

17. Tempero MA and Zetterman RK: Failure of bile salt promotion of colon cancer in the absence of the fecal stream. *Gastroenterology* 87:1612, 1985.
18. Zetterman RK, Tempero MA, Frank O, and Baker H: Vitamin content is increased in experimental rat colon adenocarcinoma. *Gastroenterology* 87:1642, 1985.
19. Lemon HM, Foley JF, Bresnick E, Kessinger MA, Birt D, Tempero M and Cohen SM: Education in Cancer Prevention. *Proc AACR*, 1985.
20. Uchida E, Tempero MA, Burnett DA, Pour PM: Correlative Studies on Antigenicity of Pancreatic Cancer and Blood Group Types. ISPO, Copenhagen. November 1985.
21. Tempero MA, Nishioka K, Wolfrey W, Zetterman R. Chemoprevention with Difluoromethylornithine (DFMO) During and After Carcinogen Exposure in Colon Cancer. *Proc AACR* 27:497, 1986.
22. Pour P, Uchida E, Tempero MA, Burnett DA and Steplewski Z: Blood Group Antigenicity of Induced Pancreatic Cancer. *Proc AACR* 27:1355, 1986.
23. Tempero MA, Uchida A, Pour PM, Burnett DA, Steplewski Z: Correlation of CA 19-9 Antigen Levels and Tumor Response in Pancreatic Cancer. *Proc ASCO* 5:51, 1986.
24. Tempero MA, Uchida E, Burnett DA, Pour PM: Relationship Between CA 19-9 and Lewis Blood Group Antigen Expression in Pts. with Pancreatic Cancer. *Gastroenterology* 90:5, 1659. 1986.
25. Tempero MA, Zetterman RK: Long Term Changes in Colon Crypt Cell Proliferation Following Single Dose Dimethylhydrazine (DMH). *Gastroenterology* 90:5, 1660. 1986.
26. Pour PM, Takasaki H, Uchida E, Tempero MA, Steplewski Z, Metzgar R. Comparative Studies on Pancreatic Cancer Antigen Expression Detected by CA 19-9 and Dupan-2. American Pancreatic Association, 1986.
27. Tempero MA, Uchida E, Takasaki H, Burnett D, Pour PM. CA 19-9 and Lewis Antigen Expression in Pancreatic Cancer. Symposium on Cancer and Smoking Related Diseases, University of Nebraska Medical Center. 1986.
28. Tempero MA, Uchida E, Takasaki H, Burnett D, Hornberger E, Steplewski Z and Pour P. CA 19-9 Levels and Tumor Response in Pancreatic Cancer. *Proc of ASCO* 6:81 Abst. #316, 1987.
29. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RG and Pour PM. Correlative Study on Expression of CA 19-9 and DU-PAN-2 in Tumor Tissue and in Serum of Patients with Pancreatic Cancer. *Proc of AACR* 28:355, Abst. #1404, 1987.
30. Sharp JG, Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, and Quaiife MA. Detection of metastasis of human colon tumor xenografts in nude mice using radiolabeled monoclonal antibody (MAb) fragments. *Clinical Nuclear Medicine* 12:32, 1987.
31. Ness MJ, Tempero MA, and Linder J. Immunohistochemistry with B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. *Modern Pathology* 1:66A, 1988.

32. Tempero MA, Colcher D, Takasaki H, Takiyama Y, Schlom J and Pour PM. Comparison of CA 19-9 and TAG 72 expression in pancreatic cancer. American Association for Cancer Research. Proc of AACR 29:385 Abst. #1531, 1988.
33. Tempero MA, Kay HD, Harvey E, Steplewski Z and Klassen L. Enhancement of both Antibody Dependent and Natural Cytotoxic Function in Pancreatic Cancer Patients given Gamma Interferon. Proc of ASCO 7:162 Abst. #624, 1988.
34. Pour PM, Tempero MA, Takasaki H, Uchida E, Takiyama Y, Burnett DA and Joshi SS, Liu C, Bliss KD, Kelly RF, Augustine SC, Crouse DA, Tempero MA, Quaife MA and Sharp JG. Comparison of Methods for Radioiodination of Monoclonal Antibody B72.3. Radiation Research Proceedings, 1988.
35. Tempero MA, Kay HD, Sivinski CL and Klassen L. Gamma interferon treatment inhibits interleukin-2 enhancement of natural cytotoxicity. Third Nebraska Symposium on Cancer and Smoking Related Diseases. February 1988
36. Lobo F, Vose J, Tempero MA, Kay HD, Sivinski C, Klassen L and Armitage JO. Failure of rIL-2 to induce LAK activity in patients with lymphoma. Proc of ASCO 8:179 Abst. #694, March 1989.
37. Tempero, M, Takasaki H, Metzgar HR and Pour PM. Tumor antigen levels predict survival in pancreatic cancer. American Society of Clinical Oncology. Proc of ASCO 8:113 Abst. #437, March 1989.
38. Haga Y, Tempero MA, Zetterman R and Kay HD. Bilirubin inhibits lymphocyte mitogenesis and interleukin-2 production. Gastroenterology 96:A605, 1989.
39. Herlyn D, Wettendorff M, Iliopoulos D, Tempero MA and Koprowski H. Idiotypic networks in cancer patients treated with monoclonal antibody. Proc of AACR 30:392 Abst. #1557, March 1989.
40. Joshi SS, Liu CN, Bliss KD, Augustine SC, Tempero MA, Crouse DA and Sharp JG. In vivo and in vitro binding of monoclonal antibody B72.3 radiolabeled using different methods. Proc of AACR 30:360 Abst. #1427, March 1989.
41. Lobo F, Tempero MA, Sivinski C, Klassen L and Kay HD. Generation of lymphokine-activated killer cells after cryopreservation of peripheral blood mononuclear cells. Proc of AACR 30:323 Abst. #1279, March 1989.
42. Tempero MA, Haga Y, Sivinski C, Kay D, and Klassen L. Absence of biologic effects with levamisole treatment. ASCO Proc 9:121, Abstr #470, 1990.
43. Kay HD, Haga Y, Uhl B, Egami H, Tempero MA, and Pour P. The Syrian hamster as a preclinical model for pancreatic cancer: in vitro antitumor IL-2-boosted cell-mediated cytotoxicity. AACR Proc 31:248, Abstr #1466, 1990.
44. Haga Y, Sivinski C, Kay HD, Blottiere H, Steplewski Z, Harvey E, and Tempero MA: Biologic responses to high dose murine monoclonal antibody infusions in pancreatic cancer patients. AACR Proc 31:254, Abstr #1501, 1990.
45. Sivinski CL, Tempero MA, Klassen L, and Kay HD. Gamma interferon treatment inhibits interleukin-2 enhancement of natural cytotoxicity. AACR Proc 31:237, Abstr #1404, 1990.

46. Haga Y, Kay HD, Tempero MA, and Zetterman RK. Novel mechanism for inhibition of phytohemagglutinin-induced proliferation in bilirubin-laden human lymphocytes. *Gastroenterology*, 98:A592, May 1990.
47. Pour PM, Egami H, Chaney W, Tempero MA, Takiyama Y and Kay HD. A preclinical model for diagnosis and therapy of pancreatic cancer. *Gastroenterology* 98:A231, May 1990.
48. Sharp JG, Joshi SS, Bliss K, and Tempero MA: Amelioration of the hematological toxicity of therapeutic levels of radiolabelled monoclonal antibody B72.3 in mice by bone marrow transplantation. *Antibody Immunonconj Pharm* 3:49, Abstr #46, 1990.
49. Tempero MA, Mitchell M, Higginbotham P: Tolerance of protracted infusion 5-fluorouracil and oral leucovorin. *ASCO Proc* 10:1160, Abstr #505, 1991.
50. Sivinski CL, Haga Y, and Tempero MA: Interleukin-2 boosted antibody dependent cellular cytotoxicity using monoclonal antibody 17-1A and pancreatic cancer cell lines. *Proc AACR* 32:329 Abst #1361, 1991.
51. Haga Y, Tempero MA, Zetterman R: Impairment of cell-mediated cytotoxicity in bilirubin-laden human lymphocytes. *Gastroenterology* 100:A749, 1991.
52. Tempero M, Joshi S, Dalrymple G, Augustine S, Harrison K, Holdeman K, Jacobson D, Jackson J, and Colcher D: Myelotoxicity in a phase I trial of radiolabeled monoclonal antibody B72.3. *Keystone Symposia on Molecular & Cellular Biology. J Cellular Biochemistry Suppl* 16A:192, 1992 Abstr #D210.
53. Tempero M, Berg A, Block M, Hutchins M, Moravec D, and Langdon R: A phase II trial of protracted therapy with 5-Fluorouracil and leucovorin in metastatic colon cancer. *ASCO Proc* 11:189, 1992 Abstr #571.
54. Sivinski CL and Tempero M: Failure to modulate tumor-associated antigens expression on human pancreatic cancer cell lines by alpha and gamma interferons. *AACR Proc* 33:302, 1992, Abstr #1799.
55. Joshi SS, Woo DV, Colcher DM, and Tempero M: In vivo internalization of monoclonal antibody 17-1A. *AACR Proc* 33:346, Abstr #2065, 1992.
56. Tempero MA, Dalrymple G, Colcher D, Joshi S, Quadri S, Linder J, Augustine S, and Leichner P: Cancer Therapy using radioimmunoconjugates: Implications for breast cancer. *Pisa Symposia in Oncology Breast Cancer: From Biology to Therapy*, 1992.
57. Harrison KA, Dalrymple GV, Leichner PK, Tempero MA, Colcher DM, Augustine SC, Bierman PJ, Joshi SS, Holdeman KP, Quadri SM, Schneiderman MH, and Jacobson DA: Clinical radiobiology of radiolabeled antibody therapy. *Proc 41st Annual Meeting of the Radiation Research Society*, pp 117, ABSTR #23-24, 1993.
58. Tempero MA, Colcher D, Dalrymple G, Harrison K, Augustine S, Schlom J, Linder J, and Leichner P: High dose therapy with ¹³¹I conjugated monoclonal antibody CC49: A phase I trial. *Antibody Immunonconj Pharm* 6:90, Abstr #84, 1993.

59. Tempero MA, Berg A, Block M, Hutchins M, Moravec D, and Langdon R. A phase II trial of protracted therapy with 5-Fluorouracil and leucovorin in metastatic colorectal cancer. ASCO Proc 12:201, 1993, Abstr #594 (poster).
60. Hansen S, Tempero MA, Sorrel M, Shaw B, Donovan J and Kumar P. Chemoradiotherapy followed by orthotopic liver transplantation (OTLT) for proximal cholangiocarcinoma (ChCA): The UNMC experience. ASCO Proc 12:226, Abstr #695, 1993.
61. Sivinski CL, Joshi SS, Colcher D, and Tempero MA. Interferon- γ modulates the antigen recognized by MAb 17-1A on HT29 colorectal carcinoma cells *in vitro*. Proc AACR 34:455, Abstr #2715, 1993.
62. Joshi SS, Jackson JD, Dalrymple DV, Colcher D and Tempero MA. Bone marrow CFU-GM is predictive of myelosuppression induced by high dose radioimmunoconjugates in intestinal cancer patients. Proc AACR 34:223, Abstr #1334, 1993.
63. Gwilt P, Lear C, Birt D, Tempero M, Grandjean A, Ruddon R, and Nagel D: Modulation of human acetaminophen metabolism by garlic extract. Proc AACR 34:556, Abstr #3313, 1993 (poster presentation).
64. Baranowska-Kortylewicz J, Bierman PJ, Quadri SM, Harrison KA, Lai J, Leichner PK, Holdeman KP, Augustine SC, Schneiderman MH, Tempero MA, Colcher DC, Jacobson DA, Dalrymple GV. Pharmacokinetics and stability of polyclonal antiferritin antibodies (RTAF) in patients with advanced Hodgkin's disease. European Journal of Nuclear Medicine 20:986, Abstr #692, 1993 (oral presentation).
65. Tempero M and Colcher D. An overview of monoclonal-based therapy in pancreatic cancer. Int J Pancreatology 16:300, 1994 (oral presentation).
66. Harrison K, Bierman P, Leichner P, Kortylewicz J, Quadri S, Holdeman K, Augustine S, Tempero M, Colcher D, Lai J, Helseth L, Schmidt B, Capadano M, Jacobson D, Kelly R, Witte R, Schneiderman M, Farnham M, and Dalrymple G: ^{90}Y Antiferritin for end-stage Hodgkin's disease. Antibody Immunoconj Radiopharm 7:92, 1994 (oral presentation).
67. Tempero M, Capadano M, and Tarassoff P. Dose escalation of Gemcitabine in previously untreated patients with pancreatic adenocarcinoma. Proc Amer Soc Clin Oncol 13:218, Abstr #660, 1994 (poster presentation).
68. Joshi SS, Sivinski CL, Bliss K, Colcher D, Tempero M. Therapeutic efficacy of internalizing ^{125}I -labeled monoclonal antibody 17-1A against human colon carcinoma. Proc AACR 35:648, Abstr #3863, 1994 (poster presentation).
69. Tempero M and Capadano M. Maintaining dose intensity of protracted infusion 5-FU with leucovorin in metastatic colorectal cancer. Proc AACR 36:241, Abstr #1434, 1995 (poster presentation).
70. Tempero M, Hansen S, Enke C, Zetterman R, Donovan J, Shaw B, and Sorrell M. Chemoradiotherapy followed by orthotopic liver transplantation (OLT) for unresectable cholangiocarcinoma (ChCA). Proc ASCO 14:193, Abstr #449, 1995 (poster presentation).

71. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Dalrymple G, and Colcher D. Phase Ia/Ib Clinical Trial of a Radioimmunoconjugate (⁹⁰Yttrium MAb CC49) in patients (pts) with Gastrointestinal Adenocarcinomas. Proc AACR, 37:611, Abstr #4189, 1996 (poster presentation).
72. Tempero, M, Leichner P, Harrison K, Baranowska-Kortylewicz N, Dalrymple G, Augustine S, and Colcher D. The emerging role of radiolabeled antibodies in cancer. Innovative Therapies in Cancer Treatment, Ravenna, Italy, November 25-26, 1995.
73. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Baranowska-Kortylewicz J, Eckblad M, Augustine SC, Tempero MA. Patient-specific dosimetry of IN-111/Y-90-labeled monoclonal antibody CC49. Society of Nuclear Medicine 43rd Annual Meeting 1996.
74. Leichner PK, Lydiatt D, Lydiatt W, Colcher D, Johansson S, Augustine S, Baranowska-Kortylewicz J, Harrison KA, Akabani G, Klein JL, Herpst JM, Hanna MG, and Tempero MA. Therapeutic potential of Yttrium-90 labeled human monoclonal antibody (⁹⁰Y-LiLo-16.88) in patients with head and neck squamous cell cancer. Sixth Conference on Radioimmunodetection & Radioimmunotherapy of Cancer, Tumor Targeting 2:173, 1996.
75. Vose J, Colcher D, Bierman P, Leichner P, Akabani G, Harrison K, Hohenstein M, Lesser S, Hammershaimb L, Goldenberg DM, Tempero M, and Armitage J. Therapy of refractory non-Hodgkin's lymphoma (NHL) with ¹³¹I-LL2 (anti-CD22) radioimmunotherapy (RIT): Results of a repetitive dosing trial. 38th Annual ASH Meeting, 1996.
76. Tempero M. Development in systemic therapy of pancreatic cancer. Ninth Annual European Cancer Conference, September 14-18. 1997.
77. Okazaki S, Tempero MA, and Colcher D. Combination Radioimmunotherapy and Chemotherapy using ¹³¹I-B72.3 and Gemcitabine. AACR Proc 39:310, Abst #2119, 1998.
78. Copur MS, Matamoros A, Capadano M, Goertzen T, McCowan T, Brand R, Lynch JC, and Tempero M: Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: A phase II trial. 35th Annual Amer Soc Clin Oncol Meeting, ASCO Proc 18:249a, Abst #955, 1999 (poster presentation).
79. Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, and Abbruzzese J: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. Fixed dose rate in metastatic pancreatic adenocarcinoma. ASCO Proc 18:273a, Abst #1048, 1999 (poster presentation).
80. Cheng JD, Knox SJ, Tempero M, Weiden PL, Horak ID, Gentner L, Bryan K, Gaffigan S, Shaller C, Adams GP, and Weiner LM: Phase II trial of NR-LU-10 pretargeted delivery of ⁹⁰Yttrium in patients with metastatic colon cancer. Proc ASCO 188:436a, Abst #1679, 1999.
81. Okazaki S, Tempero, M, Colcher, D. Combination radioimmunotherapy and chemotherapy using ¹³¹I-B72.3 and taxol. AACR Proc 40:489, Abst #3231, 1999.
82. Von Hoff D, Cox, J, Tempero M, Eder JP, Eckhardt G, Rowinsky E, Smith S, and MacDonald J: Phase II trial of Irofulven (MGI 114) in Patients with Advanced Pancreatic Cancer who have Progressed on Gemcitabine. 36th Annual American Society of Clinical Oncology Meeting. ASCO Abst # 1219, 2000.

83. Augustine, SC, Tempero, MA, Gobar, LS, Devish, KM, Colcher, DM, Baranowska-kortylewicz, J, Rtar, FJ, Norenberg, JP: Radiolabeling, quality testing and in vitro stability evaluation of I-¹³¹ HuCC49Δ2 Mab. J. of Nucl Med 41: 252P, Abst #1109, 2000.
84. Tempero, MA, MacLean, G, Palmer, M, Meikle, A, Kehoe, M, Longenecker, M. Theratope vaccine in metastatic colorectal cancer: immunogenicity and survival in a dose range study. 37th Annual American Society of Clinical Oncology Meeting, ASCO Abst # 1005, 2001. (oral presentation)
85. Blackstock, A, Tempero, MA, Niedwiecki, D, Hollis, D, Mayer, R, Tepper, J. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. ASCO Proc 20:158a, Abst #627, 2001 (poster presentation).
86. Weitzman, S, Smith, S, Eder, J, Tempero, M, Kaci, S, MacDonald, J. Irofulven monotherapy: impressive phase I and II clinical antitumor activity in heavily treated patients. ASCO Proc 20:83b, Abst #2081, 2001.
87. Ko, A, Renshaw F, Hwang, J, Lu, Y, Abbruzzese J, Brand, R, Tempero, M. Prognostic value of CA19-9 in patients with advanced pancreatic cancer receiving fixed-dose rate gemcitabine. ASCO Proc 22, Abst #1039, 2003.
88. Kulke, M. H., Niedzwiecki D., Tempero, M., Hollis, D. R., Mayer, R. J; Dana-Farber Cancer Institute, Boston, MA; Duke University Durham, NC; University of California, San Francisco, CA A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). ASCO Proc 23:315, Abst. # 4011, 2004.
89. Ko, A. H., Dito, E., Schillinger, B., Venook, A. P., Bergsland, E. K., Allen, J., Tempero, M.; UCSF Comprehensive Cancer Center, San Francisco, CA A phase II study of fixed-dose rate (FDR) gemcitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa). ASCO Proc 23:339, Abst. # 4107, 2004.
90. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Apr 1. PMID: 18379729
91. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb;26 (1):47-52.PMID: 18181045
92. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68 (3):809-16. Epub 2007 Mar 23.PMID: 1736319194.
93. Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res. 2006 Jan 1;66 (1):14-7.PMID: 16397208

94. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. *J Clin Oncol*. 2006 Jan 20;24(3):379-85. Epub 2005 Dec 12. PMID: 16344320
95. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. *J Natl Compr Canc Netw* 2005 Sep;3(5):627-36. Review. PMID: 16194454
96. Tempero MA, Behrman S, Ben-Josef E, Benson AB 3rd, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW 2nd, Melvin WS, Muscarella P 2nd, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA; National Comprehensive Cancer Network. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2005 Sep;3(5):598-626. No abstract available. PMID: 16194453
97. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. *Semin Radiat Oncol*. 2005 Oct;15(4):245-53. Review. PMID: 16183478
98. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. *Br J Cancer*. 2005 Jul 25;93(2):195-9. PMID: 15999098

PRESENTATIONS IN REGIONAL, NATIONAL AND INTERNATIONAL MEETINGS:

- “The effect of dietary fiber and high cholesterol on colon tumor incidence and size in DMH-treated rats,” Annual meeting of the American Society of Clinical Oncology, 1981.
- “The protective effect of dietary in the presence of dietary cholesterol in dimethylhydrazine (DMH)-induced colon cancer,” Annual meeting of the American Association of Cancer Research, 1982.
- “The effect of diet on thymidine (3H-TdR)-labeling of colon mucosa in dimethylhydrazine (DMH)-treated rats,” American Association of Cancer Research, 1983.
- “Sensitivity and specificity of hepatic ultrasound in the diagnosis of liver metastases,” Symposium on Liver Metastases, Leiden, The Netherlands, 1984.
- “Local effect of bile on colon crypt cell proliferation,” American Association for Cancer Research, 1984.
- Workshop on Detection of Liver Metastases. Symposium on Liver Metastases, Leiden, The Netherlands, 1984.
- “Therapy of advanced pancreatic cancer,” Symposium on Pancreatic cancer, University of Nebraska Medical Center, December 1984.

1985

- “Effect of selenium on 3H-TdR uptake in colon tissue,” Cell Kinetics Society, 1985.
- “Blood group antigenicity of induced pancreatic cancer,” American Association of Cancer Research, 1985.

“Colon Cancer Screening in High Risk Conditions,” New Developments in Cancer Therapy. Diagnostic Dilemmas: the Approach and the Answers. Keystone, Colorado, March 1985.

“Guidelines for Chemotherapy Use,” Family Practice Review Course, University of Nebraska Medical Center Continuing Education Program, April, 1985.

“Correlative studies of antigenicity of pancreatic cancer and blood group types,” International Society of Preventive Oncology, Copenhagen, Denmark, November 1985.

1986

“Murine Monoclonal Antibodies Available for Clinical Application,” Fifth Annual Congress for Hybridoma Research, Baltimore, MD 1986.

“Symposium on Colorectal Cancer,” Course Director and Moderator, Summation Statement, University of NE Medical Center, January 1986.

“Acquired Immunodeficiency Syndrome. Diagnostic Dilemmas: the Approach and the Answers,” Keystone Conference, Colorado, March 1986.

“Biological Response Modification of Cancer Therapy,” Moline, Illinois, April 1986.

“Chemoprevention with Difluoromethylornithine (DFMO) during and after carcinogen exposure in colon cancer,” American Association of Cancer Research, Los Angeles, CA, May 1986.

Gastrointestinal Endocrine Tumor Symposium, M. D. Anderson Hospital and Tumor Institute, Houston, Texas, November 1986.

“Monoclonal Antibodies and Cancer Treatment,” Loma Linda University School of Medicine and The American Cancer Society Traveling Oncology Consultant Program; Riverside General Hospital & University; Desert Hospital, Palm Springs; Presbyterian Intercommunity Medical Center, Whittier; VA Medical Center, Loma Linda; Victor Valley Community Hospital, Victorville; Hoag Memorial Hospital, Newport Beach; and Loma Linda University and Medical Center, California, December, 1986.

1987

Cancer Chemopreventive Activity of Selenium Compounds in Animal Models Workshop, National Cancer Institute, February 1987.

“NIH Centennial Celebration,” Symposium at the National Institutes of Health, May 1987.

“CO17-1A Therapy in Pancreatic Cancer,” Symposium on the treatment of pancreatic carcinoma with monoclonal antibody CO17-1A, Stockholm, Sweden, August 1987.

“Oncologic Emergencies,” University of Nebraska Medical Center, Emergency Medicine Seminar, Omaha, NE, October 1987.

“Applications of Monoclonal Antibodies in the Management of Human Pancreatic Carcinomas,” The 29th Annual Meeting of the Japanese Society of Gastroenterology Symposium in Chuo-ku, Tokyo, Japan, Nara Medical College in Nara, Japan, Kanazawa University School of Medicine in Kanazawa, Japan and The Green Cross Corporation in

Osaka, Japan, November 1987.

1988

- “Experience with CO17-1A in Pancreatic Cancer,” 17-1A Club Meeting in La Jolla, CA, February 1988.
- “Immunopathology and Immunodiagnosis of Pancreatic Neoplasms,” Gastrointestinal Pathology Society's Scientific Session, Washington, D.C., February 1988.
- “Chemoprevention Studies in Mouse Colon Cancer,” Chemoprevention Program's Decision Point Committee, National Institutes of Health, February 1988.
- “Gamma interferon treatment inhibits interleukin-2 enhancement of natural cytotoxicity,” Third Nebraska Symposium on Cancer and Smoking Related Diseases, February 1988.
- “Comparison of CA 19-9 and TAG-72 Expression in Pancreatic Cancer,” 79th Annual Meeting of the American Association for Cancer Research, New Orleans, LA, May 1988.
- “Enhancement of Both Antibody Dependent and Natural Cytotoxic Function in Pancreatic Cancer Patients given Gamma Interferon,” 24th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 1988
- “Application of Monoclonal Antibodies in Pancreatic Cancer,” Mayo Clinic, Rochester, MN, June 1988.
- “The Significance of the Human Response to Monoclonal Antibodies,” Food and Drug Administration Conference, Gaithersburg, MD, September 1988.
- “Perspectives in Colon and Pancreatic Cancer,” Oncology Update, Scottsbluff, NE, October 1988.

1989

- “Oncologic Emergencies,” Emergency Medicine Review Course, University of Nebraska Medical Center, Omaha, NE, October 1988.
- “Serodiagnosis in Gastrointestinal Tumors,” 17-1A Club Meeting, Munich, West Germany, March 1989.
- “Useful Biologic Markers in Pancreatic Cancer,” Pittsburgh Cancer Institute, Pittsburgh, PA, March 1989.
- “Update on Studies Using Monoclonal Antibodies for Treatment of Colorectal Cancer,” Recent Advances and Controversies in Colorectal Cancer Management, Peter Kiewit Conference Center, Omaha, NE, September 1989.
- “Application of Monoclonal Antibodies in Pancreatic Cancer,” M.D. Anderson Cancer Center, Houston, TX, October 1989.
- “Chemoprevention of Experimental Colon Cancer,” M.D. Anderson Cancer Center, Houston, TX, October 1989.

"Gastrointestinal Malignancies," Physician Oncology Symposium, Management of Colorectal Cancer, Moline, IL, October 1989.

1990

"Circulating Biomarkers in Gastrointestinal Cancer: Advances in Immunodiagnosis and Immunotherapy of Cancer," An Internationally Symposium Sponsored by The Wistar Institute and Holy Cross Hospital, March 1990.

"Immunotherapy," Methodist College, Nursing Symposium, March 1990.

"Amelioration of the hematological toxicity of therapeutic levels of radiolabelled monoclonal antibody B72.3 in mice by bone marrow transplantation," 5th International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA, March 1990.

"Absence of biologic effects with levamisole treatment," American Society of Clinical Oncology 26th Annual Meeting, Washington, DC, May 1990.

"Gamma interferon treatment inhibits interleukin-2 enhancement of natural cytotoxicity," American Association for Cancer Research 81st Annual Meeting, Washington, DC May 1990.

"Clinical Applications of Monoclonal Antibody in Pancreatic Cancer," Kumamoto University, Kumamoto, Japan, August 17, 1990.

"Immunotherapy with Monoclonal Antibody (MAb) in Pancreatic Adenocarcinoma," International Association of Pancreatology 4th Annual Meeting, Nagasaki, Japan, August 1990.

"Clinical Applications of Monoclonal Antibody in Pancreatic Cancer," The Royal Melbourne Hospital, Victoria, Australia, August 25, 1990; Grand Rounds, St. Vincent's Hospital, Victoria, Australia, September 1990.

"What Does Levamisole do?" Developmental Biologics Symposium, Southwest Oncology Group Fall Meeting, Columbus, Ohio, October 1990.

1991

"Clinical Application of Monoclonal Antibodies in Pancreatic Cancer," Department of Surgery, University of Lund, Lund, Sweden, March 25, 1991; Southern Swedish Oncology Society, Lund Sweden, March 26, 1991; Swedish Pancreatic Club, Soderköping, Sweden, March 27, 1991.

Design of Antibody Clinical Trials Meeting, Memorial Sloan-Kettering Cancer Center, New York, NY, December 1991.

National Institutes of Health Site Visit at University of California at Los Angeles, Los Angeles, CA, December 1991.

1992

"Systemic radiation therapy: clinical aspects," 40th Annual Scientific Meeting of the Radiation Research Society, Salt Lake City, UT, March 1992.

- “Colon Cancer and GI Malignancies,” Oncology Conference, Scottsbluff, NE
April 1992.
- “Failure to modulate tumor-associated antigens expression on human pancreatic cancer cell lines by alpha and gamma interferons,” American Association for Cancer Research, San Diego, CA, May 1992.
- “Strategies for radioimmunoconjugate therapy clinical trial design,” Symposium on MAb EMD 55 900 in Cancer Therapy, Wiesbaden, Germany, June 1992.
- “Comparative overview of results of therapy of unresectable and metastatic disease,” International Association of Pancreatology Meeting, Athens, Greece, September 1992.
- “Cancer therapy using radioimmunoconjugates: implications for breast cancer,” Pisa Symposia in Oncology, Breast Cancer: From Biology to Therapy, October 1992.
- “Pitfalls in antibody imaging in colorectal cancer,” American Cancer Society Workshop on the Pretreatment Diagnostic Management of Colorectal Cancer and Follow Up Management of Recurrent Disease, San Francisco, CA, October 1992.
- “Evaluation of radiolabeled monoclonal antibody therapy in GI tract cancers,” National Cancer Institute Workshop; US-Japan Joint Seminar Gastrointestinal Tumors Biochemical Modulation and Monoclonal Antibody; Tokyo, Japan, November 1992.
- “Application of monoclonal antibodies in pancreatic cancer,” Kumamoto University, Kumamoto, Japan, November 1992.
- “Overview of pancreatic cancer,” Grand Rounds, Mitsui Ohmuta Hospital, Kumamoto, Japan, November 1992.
- 1993**
- “Exploring monoclonal antibody therapy in pancreatic cancer,” Mt. Sinai Grand Rounds, New York, NY, February 1993.
- “High dose therapy with ¹³¹I conjugated monoclonal antibody CC49: A phase I trial,” Eighth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA, March 1993.
- “Colorectal cancer therapy update and radioimmunotherapy,” Advances in the Diagnosis and Management of Colorectal and Ovarian Cancer Symposium, Puerto Vallarta, Mexico, sponsored by the Alton Ochsner Medical Foundation, New Orleans, LA, April 1993.
- “Potential applications of monoclonal antibody for pancreatic cancer therapy,” University of Pennsylvania Cancer Center Grand Rounds, Philadelphia, PA, May 1993.
- “Phase II trial of protracted therapy with 5-Fluorouracil and leucovorin in metastatic colorectal cancer,” American Society of Clinical Oncology 29th Annual Meeting, Orlando, FL, May 1993.
- “Radioimmunotherapy,” Society of Nuclear Medicine's 40th Annual Meeting, Toronto, Ontario, Canada, June 1993.

1994

“New developments in pancreatic cancer treatment,” Medical Grand Rounds Presentation at Roswell Park Cancer Institute, Buffalo, NY, March 1994.

“Novel treatment strategies in GI malignancies,” 11th Annual Advances in Cancer Treatment Research and 6th Bone Marrow & Stem Cell Transplantation Symposium, Albert Einstein College of Medicine, New York, NY March 1994.

Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer, National Cancer Institute Organ Systems Program, Invited Chairperson, Annapolis, MD April 1994.

“Adjuvant therapy for colorectal cancer,” Centennial Celebration of the Royal Victoria Hospital, Montréal, Québec, Canada, June 1994.

“Clinical radioimmunotherapy.” 5th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, NJ, October 1994.

1995

“New strategies for the management of pancreatic cancer,” The 17th Annual Oncology Update, Cedars Medical Center, Miami, FL, February 1995.

“Management dilemmas in colorectal cancer: When to treat,” The 17th Annual Oncology Update, Cedars Medical Center, Miami, FL, February 1995.

“Gemzar (Gemcitabine HCL) phase I results prolonged infusion,” Lilly Oncology Global Medical Conference; Emerging New Treatments for Cancer: Cytotoxic to Molecular Biology. Indianapolis, IN, May 1995.

“Endpoints for evaluating the effectiveness of chemotherapy,” Lilly Oncology Global Medical Conference: Clinical Consensus: Clinical Applications for Oncologists, Chicago, IL, August 1995.

“Pancreatic tumors,” American College of Gastroenterology Post Graduate Course entitled “Management Issues in Gastroenterology--Medical and Surgical Options,” New York, NY, October 14-15, 1995.

“Pancreatic cancer -- case management,” American College of Gastroenterology Post Graduate Course entitled “Management Issues in Gastroenterology--Medical and Surgical Options.” New York, NY, October 1995.

“Issues in the management of advanced pancreatic cancer,” Iowa Oncology Society Fall Meeting, Ames, IA, October 1995.

“Colon cancer,” Meet the Professor Session, American Society of Clinical Oncology Fall Meeting. Washington, DC, November 1995.

“Dilemmas in managing advanced colorectal cancer.” 6th Annual Pittsburgh Cancer Conference, Pittsburgh, PA, November 1995.

“The emerging role of radiolabeled antibodies in cancer,” Innovative Therapies in Cancer Treatment, Ravenna, Italy, November 1995.

1996

- “Radioimmunotherapy: Will it ever work?” Minnesota Oncology Society, Rochester, MN, January 1996.
- “Thoughts on efficacy endpoints for pancreatic cancer,” Medical Oncology Divisional Conference, Mayo Clinic, Rochester, MN, January 1996.
- “Update on medical management of advanced colon cancer,” 6th International Congress on Anti-Cancer Treatment, Paris, France, February 1996.
- “Radioimmunotherapy: Will it ever work?” Brookhaven National Laboratory, Upton, NY March 1996.
- “Dilemmas in the Medical Management of Colorectal Cancer,” Current Topics in Oncology and Radiology, Ft. Wayne, IN April 1996.
- “Current issues in pancreatic cancer,” CALGB 1996 Spring Meeting, GI Committee, Miami, FL, May 1996.
- “Pancreatic Cancer - Diagnosis and treatment in 1996,” American Gastroenterological Association Fall Postgraduate Course, Chicago, IL September 1996.
- “New Opportunities for Pancreatic Cancer Management,” Association of Northern California Oncologists Meeting, San Francisco, CA, and San Jose, CA, October 1996.

1997

- “Overview single agent dose escalation studies,” Gemzar Scientific Consultants Conference, St. Thomas, U.S. Virgin Islands, February 1997.
- “Pancreatic Guidelines,” National Comprehensive Cancer Network, Second Annual Conference, Fort Lauderdale, FL, March 1997.
- “New strategies in the management of pancreatic cancer,” Huntsman Cancer Institute, University of Utah, March 1997.
- “New strategies in therapy for pancreatic cancer,” Advances in Pancreatic Cancer Treatment Symposium, Ellis Fischel Cancer Center, Columbia, MO, 1997.
- Colon Cancer Symposium Chair, 88th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 1997.
- “Dose intensity and infusion duration,” U.S. Gemzar Investigators’ Meeting, Washington, DC, May 1997.
- “New strategies in therapy for pancreatic cancer,” University of Chicago, Chicago, IL, May 1997.
- Cancer Vaccines, Co-Chair, ASCO/ESMO Session at the 33rd Annual ASCO Meeting, Denver, CO, May 1997.
- “New strategies in therapy for pancreatic cancer,” Memorial Sloan-Kettering Cancer Center, New York, NY, July 1997.

“New strategies in therapy for pancreatic cancer,” 2nd Annual Rena Schechter Memorial Lecture, Washington University at St. Louis, St. Louis, MO, September 1997.

“Development in systemic therapy of pancreatic cancer,” Integrated approach to pancreatic cancer -- A joint Federation of European Cancer Society/American Society of Clinical Oncology Symposium, Ninth Annual European Cancer Conference, Hamburg, Germany, September 1997.

“New strategies in therapy for pancreatic cancer,” University of Pennsylvania Cancer Center, Philadelphia, PA, October 1997.

“New strategies in therapy for pancreatic cancer,” Hematology-Oncology Grand Rounds, New York Hospital-Cornell University Medical Center, New York, NY, November 1997.

1998

“Progress in the management of pancreatic cancer,” 8th International Congress on Anti-Cancer Treatment, Paris, France, February 1998.

“Investigational Exclusion, Clinical Trials, and Cancer,” panelist, 3rd Annual Conference of the National Comprehensive Cancer Center, Practice Guidelines and Outcomes Data in Oncology, Ft. Lauderdale, FL March 1998.

“New advances in the treatment of pancreatic cancer,” Las Vegas Medical Oncologist Meeting, Las Vegas, NV, March 1998.

“Therapeutic applications of monoclonal antibodies,” 145th Annual Meeting and Exposition of the American Pharmaceutical Association, Ft. Lauderdale, FL, March 1998.

“Colon Cancer Research,” presented at the Cancer Update Public Forum of the American Association for Clinical Research Annual Meeting, New Orleans, LA, March 1998.

“Gemzar 30 vs. 150 Minutes Infusion in Pancreatic Cancer,” Eli Lilly and Company 1998 Oncology Global Medical Conference, Indianapolis, IN, May 1998.

“Prospects for advances in nonoperative therapy: chemotherapy, radiation, immunotherapy,” AGA Postgraduate Course entitled “Controversies and Clinical Challenges in Pancreatic Cancer”, New Orleans, LA, May 1998.

“The Management of Unresectable Pancreatic Cancer,” 1998 Digestive Diseases Week Consensus Conference, New Orleans, LA, May 1998.

“New Strategies in the Management of Pancreas Cancer,” Dana-Farber/Partners CancerCare Grand Rounds, Massachusetts General Hospital, Boston, MA, June 1998.

“New Strategies for Therapy of Pancreatic Cancer,” Hematology/Oncology Conference, University of Alabama at Birmingham, Birmingham, AL, August 1998.

“New Strategies for Therapy of Pancreatic Cancer,” Grand Rounds, University of Wisconsin Comprehensive Cancer Center, Madison, WI, August 1998.

“Radioimmunotherapy: Will It Ever Work?” Hematology/Oncology Lecture, University of Arizona Cancer Center, Tucson, AZ, September 1998.

“Pancreatic Cancer: Biologic Approaches to Treatment,” International Symposium on Pancreatic Disease: State of the Art and Future Aspects of Research, Munich, Germany, September 1998.

“Molecular Biology and Translational Approaches: Antibodies,” Third International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Köln, Germany, September 1998.

“GI Malignancies and Colon Therapies,” Society of Biological Therapy 13th Annual Meeting, Pittsburgh, PA, October 1998.

“Opportunities for Monoclonal Antibody-Based Therapy in Pancreatic Cancer,” Symposium on Pancreatic Cancer: Advances in Staging and Treatment. Memorial Sloan-Kettering Cancer Center, New York, NY, November 1998.

1999

“New Strategies for Therapy of Pancreatic Cancer,” University of California San Francisco, San Francisco, CA, January 1999.

“Contemporary Approaches to Therapy of Metastatic Colorectal Cancer,” 9th International Congress on Anti-Cancer Treatment, Paris, France, February 1999.

“How to Evaluate Noncytotoxic Drugs,” US-Japan Workshop on Clinical Trials, Tokyo, Japan, February 1999.

“Bringing Practice Guidelines to the Patients,” National Comprehensive Cancer Network Fourth Annual Conference, Ft. Lauderdale, FL, March 1999.

“Adenocarcinoma of the Pancreas,” “Chemotherapy of Pancreatic Adenocarcinoma,” “Chemotherapy and Radiation for Biliary Tract Tumors,” Gastrointestinal Cancer Conference, Park City, Utah, March 1999.

Public Forum - Ask The Experts Session - Progress and New Hope in the Fight Against Cancer, American Association for Cancer Research Annual Meeting, Philadelphia, PA, April 1999.

“NCCN/ACS Patient Information Program,” Interview on America's Health Network (AHN), Orlando, FL, Monday, April 1999.

“New Strategies for Therapy of Pancreatic Cancer,” Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Research Institute, Columbus, OH, April 1999.

“Pancreatic Cancer: Advances in Diagnosis and Treatment,” Gastrointestinal Cancer Conference, Dana Farber Cancer Institute, Boston, MA, May 1999.

“Randomized phase II trial of dose intense gemcitabine by standard infusion vs. Fixed dose rate in metastatic pancreatic adenocarcinoma,” Poster presentation - American Society of Clinical Oncology Annual Meeting, Atlanta, GA, May 1999.

“Strategies for a Successful Career in Academic Oncology,” Fellows Program, Chairperson, American Society of Clinical Oncology Annual Meeting, Atlanta, GA, May 1999.

“Novel Immunoconstructs Designed to Enhance Vascular Permeability of Solid Tumor,” 7th Annual SPORE Investigators Workshop, July 1999.

“New Strategies for Therapy of Pancreatic Cancer,” Grand Rounds, Cross Cancer Institute, Edmonton, Alberta, Canada, September 28, 1999.

“Pancreatic Cancer,” 9th World Congress of the International Gastro-Surgical Club, Nagasaki, Japan, October 1999.

Molecular Diagnostics for Digestive Malignancy, Session Co-Chair, 9th World Congress of the International Gastro-Surgical Club, Nagasaki, Japan, October 1999.

“Pancreatic Cancer,” Cancer Center Grand Rounds, University of Indiana, Indianapolis, IN, November 1999.

2000

“Progress in Treatment of Pancreas Cancer,” 10th Annual International Congress on Anti-Cancer Treatment, Paris, France, February 2000.

“Are Cancer Vaccines a Reality?”, “Are Options Slim for Cachexia?”, “Cancer of the Pancreas”, 2nd Annual Conference on Gastrointestinal Cancer, A Multidisciplinary Approach for the Clinician, Park City, UT, March 2000.

“Progress in Treatment of Pancreas Cancer,” Oncology Grand Rounds, Lomardi Cancer Center, Georgetown University Medical Center, Washington, D.C., March 2000.

“Management of Pancreas Cancer”, UCSF/Stanford Gastrointestinal Tumor Board, Silverado, CA, March 2000.

“New Therapeutics in Pancreas Cancer - Ask the Experts – Public Forum,” AACR 91st Annual Meeting, San Francisco, CA, April 2000.

“Management of Pancreas Cancer,” Redwood Regional Oncology Group Tumor Board, Santa Rosa, CA, April 2000.

“Current Chemotherapy Treatment for Advanced Pancreatic Cancer: Management of Unresectable and Metastatic Disease,” Recent Advances in the Management of Pancreatic Cancer, UCLA School of Medicine, Beverly Hills, CA April 2000.

“Strategies for a Successful Career in Academic Oncology”, “Update on the Treatment of Pancreas Cancer,” 36th ASCO Annual Meeting, New Orleans, LA, May 2000.

“Pancreatic Cancer,” Hospital Grand Rounds, Summitt Medical Center, Oakland, CA, June 2000.

“Clinical Update and Progress at UCSF,” SPORE Retreat, Eppley Institute, University of Nebraska Medical Center, Nebraska City, NE, August 2000.

“Pancreatic Cancer,” Grand Rounds, University of Virginia Health Sciences Center, Charlottesville, VA, September 2000.

“Management of Pancreas Cancer,” NCI Pancreatic Cancer Progress Review Group

Roundtable Meeting, Chantilly, VA, September 2000.

“Isotopic Immunotherapy,” Chemoradiation Summit 2000, Kaweah Delta Cancer Care Program/ St. Agnes Cancer Center/ UCSF – Stanford Health Care, Yosemite, CA, September 2000.

“Advances in Pancreatic Cancer Therapy,” Stanford Oncology Research Retreat, Stanford University, Monterey, CA, October 2000.

“Advances in the Management of Pancreas Cancer,” Grand Rounds, Johns Hopkins University Medical Center, Baltimore, MD, October 2000.

“Progress in Management of Pancreatic Cancer,” 4th Annual Cancer Symposium, Virginia Commonwealth University, MCV Hospitals, Richmond, VA, October 2000.

“New Therapies for Pancreatic Cancer,” APA/IPA Combined Meeting, Chicago, IL, November 2000.

2001

“Advances in the Management of Pancreatic Cancer,” 11th Annual International Congress on Anti-Cancer Treatment, Paris, France, February 2001.

“Advances in the Management of Pancreatic Cancer,” Seminar, Himeji National Hospital, Japan, February 2001.

“Pancreas Cancer, Quality Management in Health Care,” Kumamoto National Hospital, Kumamoto, Japan, March 2001.

“Diseases Associated with GI Cancer”, “New Developments in Chemotherapy for Pancreatic Cancer”, “Will Immunotherapy Work?”, Gastrointestinal Cancer: A Multidisciplinary Approach for the Clinical Conference, Park City, Utah, March 2001.

“Adenocarcinoma of the Pancreas,” Meet The Experts, AACR 92nd Annual Meeting, New Orleans, Louisiana, March 2001.

“Advances in the Management of Pancreatic Cancer,” Grand Rounds, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, April 2001.

“Pancreatic Cancer,” George Washington Medical Center, Washington, D.C., May 2001.

“Advances in the Management of Pancreas Cancer,” “Strategies for a Successful Career in Academic Oncology,” “Non-Colorectal Cancer – Is there a role for Combination Therapy?” 2001 ASCO Annual Meeting, San Francisco, California, May 2001.

“Pancreatic Cancer,” Institute for Continuing Healthcare Education, San Jose, California, June 2001.

“New Advances in the Treatment of Pancreatic Cancer”, Mount Diablo Regional Cancer Center, Concord, California, June 15, 2001.

“Treatment of Metastatic Pancreatic Cancer – State of the Art,” 3rd Annual Global Oncology Young Investigators’ Meeting, Chicago, Illinois, June 2001.

“New Advances in the Treatment of Pancreatic Cancer,” John Muir Medical Center, Walnut Creek, California, July 2001.

“Translational Research: From Laboratory to Clinic and Back,” “So, You Want to Be an Academic Oncologist,” 2001 Workshop on Methods in Clinical Cancer Research, Vail, Colorado, July 28 – August 2001.

“Pancreatic Cancer,” Monterey California, August 2001.

“Pancreatic Cancer,” Redwood Regional Oncology Center, Napa, California, August 2001.

“Overview of Chemotherapy for Pancreatic Cancer,” 2001 Pancreas Cancer Symposium, Virginia Mason Medical Center, Seattle, Washington, August 2001.

“Advances in the Management of Pancreas Cancer,” Sutter Cancer Center, Sacramento, California, October 2001.

“Advances in the Management of Pancreas Cancer,” Kaiser-Permanente Retreat, Rohnert Park, California, October 2001.

“Advances in the Management of Pancreas Cancer,” 39th Annual Congress of the Japan Society of Clinical Oncology, Japan, November 2001.

“Advances in the Management of Pancreas Cancer,” Rocky Mt Oncology Society, Denver, Colorado, December 2001.

“Advances in the Management of Pancreas Cancer,” University of Colorado, Denver, Colorado, December 2001.

2002

“Advances in the Management of Pancreas Cancer,” Scripps Green Cancer Center, San Diego, California, January 2002.

“Advances in the Management of Pancreas Cancer,” UC Davis Cancer Center, Davis, California, March 2002.

“Advances in the Management of Pancreas Cancer,” University of Chicago Hematology/Oncology Grand Rounds, Chicago, Illinois, April 2002.

“Advances in the Management of Pancreas Cancer,” Karmanos Cancer Institute, Grand Rounds, Detroit, Michigan, June 2002.

“Advances in the Management of Pancreas Cancer,” Chinese Anti-Cancer Association (CACA), Beijing, China, June 2002.

“Advances in the Management of Pancreas Cancer,” CSCO, Guangzhou, China, June 2002.

“Therapeutic Landscape for Pancreatic Cancer”, Gastrointestinal Cancer Research Conference, Orlando, Florida, November 2002.

2003

“Advances in the Management of Pancreas Cancer,” 13th Annual International Congress on

- Anti-Cancer Treatment, Paris, France, February 2003.
- “Advances in the Management of Pancreas Cancer,” Scripps Cancer Center Annual Conference of Hematology and Oncology, La Jolla, California, February 2003.
- “Advances in the Management of Pancreas Cancer,” Seattle Cancer Care Alliance, University of Washington, February 2003.
- “Advances in the Management of Pancreas Cancer,” Hoag Cancer Center, Newport Beach, California, February 2003.
- “Management of Pancreas Cancer,” UCSF/Stanford Gastrointestinal Tumor Board, Silverado, California, March 2003.
- “Advances in the Management of Pancreas Cancer,” GI SPORE Meeting, Arizona Cancer Center, Tucson, Arizona, March 2003.
- “Advances in the Management of Pancreas Cancer,” Medical Oncology Association of Southern California, May 2003.
- “Advances in the Management of Pancreas Cancer,” Yale Cancer Center, New Haven, Connecticut, May 2003.
- “Advances in the Management of Pancreas Cancer,” UC Davis Cancer Center, Davis, California, June 2003
- “Yes, There is Improved Survival in Patients with Advanced Pancreatic Cancer,” EPC Liverpool Meeting, University of Liverpool, England, June 2003.
- “Advances in the Management of Pancreas Cancer,” Santa Rosa Memorial Hospital, Santa Rosa, California, July 2003.
- “Advances in the Management of Pancreas Cancer,” Tumor Board, Enloe Hospital, Chico, California, August 2003.
- “New Paradigms in Pancreas Cancer Management,” ECCO Annual Conference, Copenhagen, Denmark, September 2003.
- “Treatment of Pancreatic Cancer,” 7th Biannual Conference of Hematology and Oncology, Napa, California, October 2003.
- “The Case for Chemotherapy,” ASTRO Annual Meeting, Salt Lake City, Utah, October 2003.
- “A Tale of Gemcitabine,” Memorial Sloan Kettering Grand Rounds, New York, November 2003.
- “A Tale of Gemcitabine and the Pancreas,” University of Washington, Seattle, WA, December 2003.

2004

- “The Future ASCO Strategic Plan,” Florida Society of Clinical Oncology, Florida, March 2004.

"A Translational Approach to Pancreatic Cancer Therapy," AACR Annual Meeting, Orlando, March 2004.



2004.

"Progress and Promise in Pancreatic Cancer," Sidney Kimmel Comprehensive Cancer Center, Baltimore, May 2004.

"The Management and Neoadjuvant Treatment for Pancreatic Cancer," World Congress on GI Cancer, Barcelona, June 2004.

"The Management of Pancreatic Cancer: Current Options and Future Developments," World Congress on GI Cancer, Barcelona, June 2004.

"An Overview of Pancreatic Cancer Therapy," World Congress on GI Cancer, Barcelona, June 2004.

"Status of Oncology in America: State of the Field," Update on the Management of Gastrointestinal Malignancies, Colorado Springs, Colorado, July 2004.

"Current Management of Pancreatic Cancer," ACORD (Australia & Asia Pacific Clinical Oncology Research Development) Workshop, Palm Cove, Australia, August 2004.

"Neo-Adjuvant Therapy of Upper GI cancer," ACORD (Australia & Asia Pacific Clinical Oncology Research Development) Workshop, Palm Cove, Australia, August 2004.

"Progress and Promise in Pancreatic Cancer," Northwestern University, Medical Grand Rounds, Chicago, IL, September 2004.

"Treatment of Systemic disease," Fifth International Conference on Biology, Prevention and Treatment of GI-Malignancies, Essen, Germany, September 2004.

"Therapeutic Landscapes in Pancreatic Cancer," The 3rd Annual Symposium on Gastrointestinal Cancers: An Update on Advances in Diagnosis and Management, St. Louis, MO, October 2004.

"Therapeutic Landscapes in Pancreatic Cancer," Halle, Germany, October 2004.

"How to Create a Successful Clinical Unit," 29th Annual European Society of Medical Oncology Congress, Vienna, Austria, November 2004.

"Therapeutic Landscapes in Pancreatic Cancer," Annual APA Meeting, Northwestern University, Chicago, IL, November 2004.

2005

"Therapeutic Landscape for Pancreatic Cancer," 3rd SAGE Meeting, Versailles, France, January 2005.

“New Paradigms in Pancreatic Cancer Management,” 16th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, February 2005.

“The Therapeutic Landscape for Pancreatic Cancer,” Stanford Digestive Disease Center Symposium, Stanford, CA June 2005.

“Approach to Patients with Metastatic Pancreatic Cancer,” 7th World Congress on GI Cancer, Barcelona, Spain, June 2005.

“Career Development Workshop for fellows and Junior Faculty: How to choose a career that is right for you,” ASCO Annual meeting, Orlando, FL, May 2005.

“Chemotherapy of Pancreatic Cancer,” “Ten Years of Gemcitabine in the Treatment of Solid Tumors” First International Conference on Cancer by the National Cancer Institute of Veneto, Monstier di Treviso, Italy, September 2005.

“Cancer Treatment in the future,” Multi-Model Treatment of GI Cancer, Oslo, Norway, September 2005.

“Novel Therapeutics – the End of Nihilism,” National Cancer Research Institute Symposium, Birmingham, UK, October 2005.

“New Frontiers in the Therapeutic Landscape for Metastatic Pancreatic Cancer,” ECCO 13, Federation of European Cancer Society, Paris, France, November 2005.

“The Therapeutic Landscape of Pancreatic Cancer,” IJB Prestige Seminar, Brussels, Belgium, November 2005.

“Challenging Case Studies in Pancreatic Cancer,” First Annual World Oncology Congress, New York, NY, November 2005.

2006

“New Trends in the Treatment of Pancreatic Cancer,” NCCN 11th Annual Conference, Hollywood, FL, March 2006.

“Pancreatic Adenocarcinoma: The Last Frontier,” Grand Rounds at University of North Carolina Lineberger Comprehensive Cancer Center, May 2006.

“Molecular Changes in Pancreatic Cancer,” 8th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 2006.

“New Frontiers in Pancreatic Cancer,” National Cancer Institute Imaging Science Workshop, Gaithersburg, MD, July 2006.

“Improving Survival in Pancreatic Cancer: Not an Easy Job,” [REDACTED] Investigators’ Meeting, August 2006.

“How to improve outcome in pancreatic cancer,” Scientific Symposium at opening of Ullevål University Hospital Cancer Center, Oslo, Norway, October 2006.

“Radiation and Pancreatic Cancer: the Great Debate,” 31st ESMO Congress, Istanbul, Turkey, October 2006.

“Fighting Cancer: A Progress Report,” Meeting of Northern California Cancer Registrars’ Association, December 2006.

2007

“The Argument for Adjuvant Therapy,” ASCO GI Symposium, Orlando, FL, January 2007.

“Pancreas Cancer Treatment: Looking Into the Future,” 18th International Congress on Anti-Cancer Treatment, Paris, France, February 2007.

“Advanced Pancreatic Cancer: Looking for the optimum treatment,” 5th International Postgraduate Course: Frontiers in HPB Diseases, Athens, Greece, March 2007.

“State of the Art Diagnostic and Treatment Methods for Pancreatic Cancer,” 12th Annual NCCN Conference, March 2007.

“Fighting Cancer: A Progress Report,” St. Francis Hospital, Medical Grand Rounds, San Francisco, CA, March 2007.

“Colorectal Cancer: A Progress Report and Look to the Future,” Clinical Oncology in Croatia – Strategic Planning and Beyond, Zagreb, Croatia, May 2007.

“The ESO Colorectal Cancer Observatory: a look into the future,” 3rd ESO Colorectal Cancer Observatory Session, Barcelona, Spain, June 2007.

“Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer,” 9th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 2007.

“Pancreatic Adenocarcinoma: The Last Frontier,” University of California, San Francisco, Medical Grand Rounds, San Francisco, CA, August 2007.

“State of the Art Diagnostic and Treatment Methods for Pancreatic Cancer,” [REDACTED] Clinical Oncology Workshop [REDACTED] 2007.

“Current Treatment Regimens and US/EU/ROW Treatment Guidelines for Pancreatic Cancer,” [REDACTED] Pancreatic Advisory Board Meeting [REDACTED] 2007.

2008

“Pancreatic Adenocarcinoma: The Last Frontier,” Zhongshan City Peoples Hospital, Zhongshan, China, January 2008

“Pancreatic Adenocarcinoma: The Last Frontier,” Shanghai Cancer Hospital and Cancer Institute, Shanghai, China, January 2008

“Pancreatic Adenocarcinoma: The Last Frontier,” PUMC – Peking Union Medical College, Peking, China, January 2008

“Impact of the Current Environment on Pan-GI Cancers,” [REDACTED] 2008.

“Current Role of Targeted Agents in the Therapy of Pancreas Cancer: Status of EGFR Inhibition/Anti-angiogenic Agents,” CBCE – Center for Biomedical Continuing Education, San Francisco, CA March 2008.

“Pancreatic Cancer Treatment: Can a Phoenix Rise from the Ashes?” Vanderbilt-Ingrim, Nashville, Tennessee, May 2008

**APPEARS THIS WAY
ON ORIGINAL**